Hypercalcemia …

Douglas J Lanska MD MS MSPH

General Neurology

Updated 05.14.2024
Released 11.03.1993
Expires For CME 05.14.2027

Hypercalcemia

Author: Douglas J Lanska MD MS MSPH

See Contributor Disclosures

Hypercalcemia

In This Article

Quick Link

Introduction

Overview

Hypercalcemia is associated with a broad range of neurologic manifestations that have been ascribed to both central nervous system and peripheral nervous system dysfunction. Reported neurologic manifestations can include weakness, fatigue, confusion, posterior reversible leukoencephalopathy syndrome, a Creutzfeldt-Jakob–like syndrome due to hypercalcemic encephalopathy, stupor, and coma. It remains unclear if the weakness associated with hypercalcemia is primarily due to both central nervous system and peripheral nervous system effects of hypercalcemia. In this article, the author reviews the clinical spectrum of neurologic dysfunction associated with hypercalcemia, as well as the evaluation and management of hypercalcemia.

Key points

	• Depending on the severity and rate of development, hypercalcemia can produce varying degrees of a generalized encephalopathy ranging from mild impairment of attention to coma.
	• Primary hyperparathyroidism and malignancy-associated hypercalcemia are the most common causes of hypercalcemia, together accounting for more than 90% of cases.
	• Hypercalcemia in the setting of malignancy is a common oncologic emergency and develops in 20% to 30% of patients with cancer.
	• For patients with severe hypercalcemia (greater than 13.5 mg/dL) or moderate hypercalcemia and significant clinical manifestations, the initial management entails strategies that directly lower the calcium concentration, independent of the underlying cause.

Historical note and terminology

The parathyroid glands were discovered (but not named) in 1852 by comparative anatomist and paleontologist (later Sir) Richard Owen (1804-1892) in the necropsy of an Indian rhinoceros that died at the London Zoo (217; 61; 43; 124; 96). In his description, Owen referred to the glands as "a small compact yellow glandular body attached to the thyroid at the point where the veins emerged" (217; 61). The significance of this report was only evident in retrospect, and Owen was much more famously recognized for naming the Dinosauria (ie, dinosaurs) in the 1830s and infamously as an antievolutionist opposed to Charles Darwin and his proponent Thomas Huxley after publication of Darwin’s The Origin of Species by Means of Natural Selection (1859) (182; 110; 111; 99; 226). Although Owen was notorious for usurping the work of others and passing it off as his own, in this case Owen was apparently responsible for the observation, although he had no idea of its significance.

British surgeon and anatomist Richard Owen

British surgeon and anatomist Richard Owen (1804-1892) c1856 with the skull of a crocodile. In 1852, Owen discovered the parathyroid glands in the necropsy of an Indian rhinoceros. However, he neither named the glands, nor underst...

Unaware of Owen’s earlier work, published as it was in what was then a relatively obscure society proceeding, the parathyroid glands were identified decades later in humans in 1880 by Ivar Sandstrom (1852-1889), a 25-year-old medical student working as a praelector (lecturer) in anatomy at the University of Uppsala, Sweden (234; 235; 48; 58; 143; 144). In his classic paper, On a New Gland in Man and Fellow Animals (in translation), he described what he called the “glandulae parathyroidae” (parathyroid glands) in dogs, cats, rabbits, oxen, horses, and man (gross and micro). Sandstrom’s principal interest was the organ in man, and he examined 50 individuals and found in most of them two parathyroid glands on each side. Unfortunately, Sandstrom's report was not well received and he later committed suicide at age 37 years.

Swedish physician and anatomist Ivar Sandstrom (1852-1889)

In 1880, Sandstrom identified the parathyroid glands in man and various other mammals. (Courtesy of Wikipedia and Wellcome Library. Public domain.)
Parathyroid glands (gross appearance)

Gross appearance of the parathyroid glands (marked as “gl. pth.” in the Figure) in man as illustrated by Swedish physician and anatomist Ivar Sandstrom in 1880. (Public domain.)
Parathyroid glands (microscopic appearance)

Microscopic appearance of the parathyroid glands in man as illustrated by Swedish physician and anatomist Ivar Sandstrom in 1880. (Public domain.)

The clinical importance of the parathyroid glands was not appreciated until 1891, when French physiologist Eugène Émile Gley (1857-1930) observed that tetany and death following experimental thyroidectomy in dogs occurred only if the excised material included the glandulae parathyroidae described by Sandström (104). To this point, tetany in association with thyroidectomy had been misattributed to removal of the thyroid gland. Because of Gley’s discovery, parathyroid glands have sometimes been referred to as "Gley's glands."

French physiologist Eugène Émile Gley (1857-1930)

Gley observed that tetany and death following experimental thyroidectomy in dogs occurred only if the excised material included the glandulae parathyroidae (parathyroid glands) described by Ivar Sandstrom in 1880. (Courtesy of the...

From 1903 to 1908, American pathologist William G MacCallum (1874-1944) and Swiss-U.S. pharmacologist (and later the first head of the U.S. National Cancer Institute from 1938-1943) Carl Voegtlin (1879-1960), both working at Johns Hopkins, demonstrated that tetany following parathyroidectomy was the result of the hypocalcemia (181; 180; 141; 185; 86). Not only was there a “marked reduction in the calcium content of the tissues especially of the blood and brain, during tetany” following parathyroidectomy, but the “injection of a solution of a salt of calcium into the circulation of an animal in tetany promptly checks all the symptoms and restores the animal to an apparently normal condition.” MacCallum and Voegtlin also showed that variable production of tetany following parathyroidectomy in animal experiments depended on the presence of residual parathyroid tissue, a result that was not infrequent because of the variable number and location of the parathyroid glands. In 1909, William B Berkeley and S P Beebe, at Cornell University Medical College in New York, described correction of hypocalcemic tetany with parathyroid extract in man (38).

American pathologist William G MacCallum (1874-1944)

From 1903 to 1908, MacCallum studied the effects of parathyroidectomy. In 1908, MacCallum and colleague Carl Voegtlin, both working at Johns Hopkins, demonstrated that tetany following parathyroidectomy was the result of the hypoc...
Swiss-American pharmacologist Carl Voegtlin

Swiss-American pharmacologist (and later the first head of the U.S. National Cancer Institute) Carl Voegtlin (1879–1960). In 1908, Voegtlin and colleague William G MacCallum, both working at Johns Hopkins, demonstrated that tetany...

In 1891, German pathologist Friedrich Daniel von Recklinghausen (1833-1910) described osteitis fibrosa cystica, which is characterized by a loss of bone mass, a weakening of the bones as their calcified supporting structures are replaced with fibrous tissue (peritrabecular fibrosis), and the formation of cyst-like brown tumors in and around the bone. This is also known as osteitis fibrosa, osteodystrophia fibrosa, and Recklinghausen disease of bone (which should not be confused with Recklinghausen disease, neurofibromatosis type I). By 1914 Austrian pathologist Jacob Erdheim (1874-1937), working in Vienna, suggested that parathyroid pathology may cause skeletal abnormalities, and this was documented the following year by Z Schlagenhaufer from the observation that in patients with osteitis fibrosa cystica, only one parathyroid gland is typically enlarged (ie, a parathyroid adenoma). If the parathyroid enlargement had been somehow due to or in response to the bony changes, then all of the parathyroid glands routinely should have been similarly enlarged. This ultimately led to the use of parathyroidectomy as a treatment for osteitis fibrosa cystica beginning in 1925.

German pathologist Friedrich Daniel von Recklinghausen

German pathologist Friedrich Daniel von Recklinghausen (1833-1910) is most known for his monograph in 1882 (Über die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen) in which he reviewed previous literature...
Osteitis fibrosa cystica (x-ray)

Osteitis fibrosa cystica is characterized by a loss of bone mass, a weakening of the bones as their calcified supporting structures are replaced with fibrous tissue (peritrabecular fibrosis), and formation of cyst-like brown tumor...
Austrian pathologist Jacob Erdheim (1874-1937)

By 1914 Erdheim, working in Vienna, suggested that parathyroid pathology may cause skeletal abnormalities. Photograph reproduced with permission from Erdheim’s great niece, Claudia Erdheim. The image is the private property of Cla...

Parathyroid surgery began before that, though. British surgeon Sir John Bland-Sutton (1855-1936) had described a postmortem specimen of a parathyroid tumor in 1886, had surgically removed a parathyroid cyst in 1909, and had performed a parathyroidectomy for a parathyroid tumor some time before 1917 (79). In 1907, Herbert M Evans, working with American surgeon William Stewart Halsted (1852-1922) at Johns Hopkins in Baltimore, described the vascular supply of the parathyroid glands in man, and in the same paper Halsted discussed preservation of the parathyroid glands with thyroid surgery (117). Evans careful drawing of the parathyroid glands was later used by anatomist Henry Gray in his Anatomy of the Human Body (1918). In 1909, Halsted attempted both iso- and auto- transplantation of parathyroid tissue by transplanting canine parathyroid glands into thyroid tissue and under the skin (116). In 1925, Viennese surgeon Felix Mandl (1892-1957), at the Hochenegg Clinic, performed a successful parathyroidectomy as a means of alleviating the bone disease of hyperparathyroidism; his patient was a 34-year-old tram-car conductor with severe osteitis fibrosa cystica (186).

British surgeon Sir John Bland-Sutton (1855-1936)

Bland-Sutton had described a postmortem specimen of a parathyroid tumor in 1886, had surgically removed a parathyroid cyst in 1909, and had performed a parathyroidectomy for a parathyroid tumor some time before 1917. (Courtesy of ...
American surgeon William Stewart Halsted (1852-1922)

In 1909, Halstead, working at Johns Hopkins in Baltimore, attempted both iso- and auto-transplantation of parathyroid tissue, by transplanting canine parathyroid glands into thyroid tissue and under the skin. (Courtesy of the U.S....
Parathyroid glands (drawing)

Drawing of the parathyroid glands by Herbert M Evans, working with American surgeon William Stewart Halsted (1852-1922). Evans careful drawing of the parathyroid glands was subsequently used in a later edition (1918) of Anatomy of...

In 1923 Adolph M Hanson (1880-1959), and two years later Canadian biochemist James B Collip (1892-1965) independently isolated parathyroid hormone from crude glandular extracts (123; 92; 119; 120; 121; 122; 70; 70; 211; 271; 49; 30; 175; 176; 147). The purification of parathyroid hormone greatly accelerated experimental studies to determine the effect of the hormone on bone and kidneys. In addition, American medical physicist Rosalyn Sussman Yalow (1921-2011) successfully developed radioimmunoassays for peptide hormones, including parathyroid hormone (42; 39; 39; 40; 41; 249; 273). Yalow was awarded a Nobel Prize for Physiology or Medicine in 1977.

Canadian biochemist James B Collip (1892-1965)

In 1923, following the earlier work of Adolph M Hanson, Collip isolated parathyroid hormone from crude glandular extracts. (Courtesy of Wikipedia. Public domain.)
American medical physicist and Nobel laureate Rosalyn Sussman Yalow (1921-2011)

Yalow successfully developed radioimmunoassays for peptide hormones, including parathyroid hormone. (Courtesy of Wikipedia. Public domain.)

From the late 1920s until 1956 (when he suffered a career-ending postoperative complication of chemopallidectomy for early-onset Parkinson disease, ie, intracranial hemorrhage with resulting akinetic mutism), American endocrinologist Fuller Albright (1900-1969) and associates at the Massachusetts General Hospital in Boston studied numerous aspects of disordered parathyroid gland function and conducted landmark metabolic balance studies that clearly defined several of the diseases associated with parathyroid dysfunction, as well as related disorders of calcium and phosphorus metabolism (34; 06; 04; 05; 07; 09; 15; 14; 16; 02; 18; 134; 03; 03; 68; 50; 11; 12; 193; 72; 22; 26; 32; 33; 127; 131; 166; 257; 132; 89; 219; 154; 153; 97; 187). In 1929 Albright colleague Read McLane Ellsworth (1899-1970) diagnosed a first case of idiopathic hypoparathyroidism (10). Albright and colleagues noted that most patients treated with parathyroidectomy for primary hyperparathyroidism and osteitis fibrosa cystica also had nephrolithiasis or nephrocalcinosis (06), established the concept of secondary hyperparathyroidism (06), described hyperparathyroidism due to adrenal hyperplasia (06), described vitamin D-resistant rickets and effective treatment with high doses of vitamin D (08), established a primary effect of vitamin D is to increase intestinal absorption of calcium (16), and described postmenopausal osteoporosis (02), hypercalcemia with disuse osteoporosis (02), pseudohypoparathyroidism (18), the milk-alkali syndrome (17), pseudo-pseudohypoparathyroidism (11), and idiopathic hypercalciuria (12).

The subsequent assay, sequencing, and cloning of parathyroid hormone led to the further elaboration of the multiple actions of the hormone and of the abnormalities associated with dysfunction of the parathyroid glands.

In 1957, Walter T St Goar, at the College of Physicians and Surgeons of Columbia University in New York, emphasized the abdominal manifestations of hyperparathyroidism and proposed a mnemonic triad for recognizing the disorder as a “disease of stones, bones and abdominal groans” (252). St Goar had been influenced to pursue studies in this area by Fuller Albright while St Goar and his wife were interns and residents at Massachusetts General Hospital. As St Goar elaborated (252):

Gastrointestinal symptoms appear to represent a clue to the earlier recognition of some cases of hyperparathyroidism…Unexplained episodes of nausea and vomiting, unexplained anorexia and weight loss, peptic ulcers which do not respond in the usual way to therapy, [marked constipation,] and a variety of unexplained abdominal pains should all lead to a consideration of hyperparathyroidism as a possible diagnosis. Hyperparathyroidism, which has been popularly thought of by medical men as a ‘disease of stones and bones,’ might be recognized both earlier and more frequently if it were widely regarded as a ‘disease of stones, bones and abdominal groans.

St Goar recognized that the abdominal manifestations of hyperparathyroidism are nonspecific, but he hoped that greater recognition of their prominence in this disorder might speed clinical recognition and treatment (252):

These gastrointestinal symptoms are meaningless in themselves. An awareness of their occurrence in hyperparathyroidism, however, may prove helpful in recognizing other nonspecific manifestations of a potentially reversible disease and thus lead to its earlier diagnosis.

In 1961, William C Mieher Jr., Yvan Thibaudeau, and Boy Frame, at Henry Ford Hospital in Detroit, emphasized the neuropsychiatric features of hyperparathyroidism, which can include apathy, agitated depression, psychosis with hallucinations or delusions, paranoia, and dementia. They modified St Goar’s mnemonic triad into a mnemonic quadrad by adding “psychic moans” to reflect the neuropsychiatric manifestations: “we wish to add a postscript to St Goar's description and emphasize that hyperparathyroidism is a disease of stones, bones, abdominal groans, and psychic moans” (197).

In 1965 Charles E Boonstra and Charles E Jackson, at the Caylor-Nickel Clinic in Bluffton, Indiana, emphasized the chronic fatigue and nonspecific irritability seen in many patients with hyperparathyroidism (46). Boonstra further modified the existing mnemonic for hyperparathyroidism from a quadrad into a pentad by adding “fatigue overtones” to reflect the fatigue and “nervous irritability” often seen in patients with hyperparathyroidism even when more specific findings are either absent or not clinically manifest (46):

The majority of patients with hyperparathyroidism manifested nonspecific fatigue and nervous irritability that were alleviated by excision of the parathyroid adenoma. The tiredness noted by many patients…was often present in our patients on arising even though it became worse with activity and was partially relieved by resting. St. Goar (1957) proposed that hyperparathyroidism be thought of as a disease of ‘stones, bones and abdominal groans’ to which Mieher, Thibaudeau, and Frame (1961) added ‘and psychic moans.’ Perhaps this statement should be amplified to ‘stones, bones, abdominal groans, and psychic moans with fatigue overtones.

Clinical manifestations

Presentation and course

	• Hypercalcemia is often asymptomatic, and more than half of cases are identified by an unanticipated elevation in serum calcium on biochemical screening studies, whereas other cases present with symptoms and signs of their underlying diseases (eg, bone pain from osseous metastases or kidney stones in hyperparathyroidism).
	• Symptoms and signs of hypercalcemia per se depend on the severity and rate of development of the hypercalcemia.
	• Patients with serum calcium levels less than 11 mg/dl are rarely symptomatic from hypercalcemia, whereas those with levels between 11 mg/dl and 14 mg/dl may be symptomatic, and those with levels above 14 mg/dl are uniformly symptomatic and at risk of severe organ damage.
	• Ectopic soft-tissue calcification is increasingly likely as serum calcium levels rise above 13 mg/dl.
	• Symptoms tend to be more likely and more severe if hypercalcemia develops rapidly.
	• Hypercalcemia can cause a broad range of nonspecific systemic manifestations, including dehydration, fatigue, weight loss, anorexia, constipation, nausea, vomiting, abdominal pain, and pruritus.
	• The most specific sign of chronic hypercalcemia is band keratopathy, a condition in which metastatic calcification occurs in the medial and lateral margins of the cornea adjacent to the scleral limbus.
	• Depending on the severity and rate of development, hypercalcemia can produce varying degrees of a generalized encephalopathy, ranging from mild impairment of attention to coma.
	• Patients with hypercalcemic encephalopathy can also present with a posterior reversible leukoencephalopathy syndrome, or a subacute Creutzfeldt-Jakob-like syndrome of progressive dementia.
	• Weakness is a common symptom of hypercalcemia.
	• Hypercalcemia in the setting of malignancy is a common oncologic emergency and ultimately develops in 10% to 30% of patients with cancer.

Hypercalcemia is often asymptomatic, and more than half of cases are identified by an unanticipated elevation in serum calcium on biochemical screening studies. Other cases present with symptoms and signs of their underlying diseases (eg, bone pain from osseous metastases or kidney stones in hyperparathyroidism). Symptoms and signs of hypercalcemia per se depend on the severity and rate of development of the hypercalcemia (270). Patients with serum calcium levels less than 11 mg/dl are rarely symptomatic from hypercalcemia, whereas those with levels between 11 mg/dl and 14 mg/dl may be symptomatic, and those with levels above 14 mg/dl (severe hypercalcemia) are uniformly symptomatic and at risk of severe organ damage. Ectopic soft-tissue calcification is increasingly likely as serum calcium levels rise above 13 mg/dl. Symptoms tend to be more likely and more severe if hypercalcemia develops rapidly.

Hypercalcemia can cause a broad range of nonspecific systemic manifestations, including dehydration, fatigue, weight loss, anorexia, constipation, nausea, vomiting, abdominal pain, and pruritus. Most of these can be traced to dysfunction of the renal, cardiovascular, and gastrointestinal systems (88; 63; 135; 44), and in the setting of malignancy-associated hypercalcemia may be difficult to differentiate from tumor- or treatment-related symptoms (170). Hypercalcemia impairs the ability of the renal tubules to respond to antidiuretic hormone (vasopressin), causing a form of nephrogenic diabetes insipidus that decreases the ability of the kidneys to concentrate the urine by removing free water, which in turn produces polyuria and contributes to dehydration (as do nausea and vomiting). Other renal effects include azotemia, renal stones, and nephrocalcinosis (ie, deposition of calcium salts in the renal parenchyma). Cardiovascular manifestations include atrial or ventricular arrhythmias, and the arrhythmogenic effects of hypercalcemia may be potentiated by concomitant therapy with digitalis or by underlying cardiac disease (268). Anorexia, nausea, vomiting, constipation, and ileus are common gastrointestinal symptoms; pancreatitis and peptic ulcer disease are less common associated conditions involving the gastrointestinal system.

Primary hyperparathyroidism is the most common cause of hypercalcemia and is most often identified in postmenopausal women with hypercalcemia and parathyroid hormone (PTH) levels that are either elevated or inappropriately normal (247). The clinical presentation of primary hyperparathyroidism includes three types: (1) target organ involvement of the renal and skeletal systems; (2) mild asymptomatic hypercalcemia; and (3) high PTH levels in the context of persistently normal albumin-corrected and ionized serum calcium values. Factors that influence the clinical presentation include the extent to which biochemical screening is employed, the prevalence of vitamin D deficiency, and whether PTH levels are a routine part of the evaluation of osteopenia and osteoporosis. When biochemical screening is common, asymptomatic primary hyperparathyroidism is the most likely presentation. If vitamin D deficiency is prevalent and biochemical screening is routinely employed, symptomatic disease with skeletal abnormalities is the likely presentation. Finally, when PTH levels are used in the evaluation of low bone mineral density, the normocalcemic presentation is likely.

Osteoclastic bone resorption in hyperparathyroidism causes loss of bone mineral density and, in advanced cases, peritrabecular fibrosis and cyst-like brown tumors in and around the bone, producing "osteitis fibrosa cystica." These advanced changes produce softening of the bones, fragility-related bone fractures, and a moth-eaten appearance of the bones on x-ray studies. Osteitis fibrosa cystica was first described by Gerhard Engel in 1864 and Friedrich Daniel von Recklinghausen in 1890 but is now infrequently seen. Less advanced loss of bone mineral density in hyperparathyroidism still increases the risk of fragility-related bone fractures.

Hand x-rays in hyperparathyroidism

X-ray of the hands showing brown tumors in a patient with hyperparathyroidism. (Contributed by Ahmed Haroud. Courtesy of Radiopaedia.org and Wikipedia.)
German pathologist Friedrich Daniel von Recklinghausen

German pathologist Friedrich Daniel von Recklinghausen (1833-1910) is most known for his monograph in 1882 (Über die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen) in which he reviewed previous literature...

The most specific sign of chronic hypercalcemia is band keratopathy, a condition in which metastatic calcification occurs in the medial and lateral margins of the cornea adjacent to the scleral limbus. Band keratopathy differs in appearance from arcus senilis, which begins superiorly and inferiorly and eventually extends around the margins of the cornea (annulus senilis) (279).

Band keratopathy

Band keratopathy in a patient with aphakia (due to congenital cataracts) and a history of partial iridectomy. Note the white calcium deposits along the medial and lateral margins of the cornea adjacent to the scleral limbus. (Phot...
Arcus senilis

Arcus senilis (for comparison with band keratopathy). (Source Loren A Zech Jr and Jeffery M Hoeg 2008.)

Depending on the severity and rate of development, hypercalcemia can produce varying degrees of a generalized encephalopathy, ranging from mild impairment of attention to coma. Between these two extremes, patients commonly manifest an acute confusional state associated with apathy, depression, or lethargy (218). Personality changes and psychosis have also been described (261; 63; 282; 216), although primary hyperparathyroidism may present with various severe psychiatric symptoms, even in mild hypercalcemia (216). Rarely, other neurologic manifestations may occur, including seizures (60) and parkinsonism (214).

Several case reports have highlighted patients with hypercalcemia who presented with a posterior reversible leukoencephalopathy syndrome (150; 65; 210). Hypercalcemia associated with posterior reversible leukoencephalopathy syndrome was due to a variety of causes, including excessive oral intake of calcium, plasmacytoma, carcinoma, and AIDS-associated mycobacterial infection. Although immune suppression and arterial hypertension are well known to predispose patients to the development of posterior reversible leukoencephalopathy syndrome, isolated hypercalcemia in normotensive immunocompetent patients is a relatively recently described etiology (150; 65; 210).

Patients with hypercalcemic encephalopathy can also present with a subacute Creutzfeldt-Jakob-like syndrome of progressive dementia (228). EEG may show bursts of 1.5 to 2 Hz intermittent rhythmic delta activity superimposed on low-voltage background activity. Unlike in Creutzfeldt-Jakob disease, myoclonic jerks and periodic discharges are rare in hypercalcemic encephalopathy. Clinical and EEG abnormalities may resolve after normalization of serum calcium levels.

Weakness is a common symptom of hypercalcemia, and one that may have multiple etiologies. Although the pathophysiology of objective weakness due to hypercalcemia is not always clear, it is thought to be primarily a manifestation of CNS dysfunction, based on the presence of hyperreflexia and extensor plantar responses in some well-detailed case reports, and the lack of convincing evidence of dysfunction within the motor unit (165). At times, weakness and muscle wasting occur in combination with brisk muscle stretch reflexes, and the clinical picture can mimic amyotrophic lateral sclerosis. Some have postulated a neurogenic source of weakness in such cases. However, the proposal that hyperparathyroidism can cause a form of motor neuron disease remains highly contentious (220; 165; 137). The presence of paraparesis or quadriparesis and upper motor neuron signs, with or without a sensory level, should also prompt consideration of spinal cord compression due to a brown tumor arising in a vertebral body, a rare complication of primary or secondary hyperparathyroidism (261). In addition, in the setting of primary hyperparathyroidism, instances of true myopathy have been documented with support from electrophysiologic and histologic studies, but such cases appear to be uncommon (264; 164; 148).

Hypercalcemia in the setting of malignancy is a common oncologic emergency and ultimately develops in 10% to 30% of patients with cancer (253; 170; 229; 105). Hypercalcemia due to malignancy is the most common cause of hypercalcemia in hospitalized patients (19). Overall, the point prevalence of hypercalcemia among cancer patients is only about 2% to 3% (102), but the prevalence is greater in patients with advanced cancer. The point prevalence of hypercalcemia of malignancy varies by tumor type and is highest for patients with multiple myeloma (8% to 10%) and lowest among colorectal and prostate cancer patients (102). Patients with malignancy-related hypercalcemia can present with a prominent encephalopathy, dehydration, and generalized weakness. Hypercalcemia is the most common life-threatening metabolic disorder in patients with advanced-stage cancers and is a poor prognostic indicator (24).

Prognosis and complications

Malignancy-associated hypercalcemia has a dire prognosis: the mean survival in patients with cancer once hypercalcemia supervenes is approximately 30 days. The prognosis of hypercalcemia is otherwise excellent, provided that the underlying disease is identified and appropriately treated.

Severe hypercalcemia itself is not generally immediately life-threatening (113). A retrospective observational study over a 5-year period of patients admitted to the adult emergency department of a large tertiary hospital found no cases of immediately life-threatening cardiac arrhythmias or neurologic complications associated with hypercalcemia above 4 mmol/l (16 mg/dl) (113).

Clinical vignette

A 55-year-old woman was brought to the emergency room by her family because of increasing confusion. Her family reported that she had been depressed and withdrawn for many months, but she had recently become less responsive and more somnolent. She was diagnosed with breast cancer 6 months earlier and was treated with modified radical mastectomy and radiation. Review of systems was remarkable for complaints of headache, polyuria, and lightheadedness on standing. Neurologic examination showed a decreased level of arousal, poor attention, and an inability to follow complex commands. Cranial nerve, motor, sensory, coordination, and muscle stretch reflex examinations were unremarkable. Plantar responses were downgoing. Serum calcium was 14 mg/dL (3.5 mmol/L). A bone survey revealed multiple osteolytic metastatic lesions. Initial treatment included volume expansion with normal saline, calcitonin, and zoledronic acid.

Biological basis

	• Calcium is transported through the bloodstream as dissolved divalent cations (Ca2+) or bound to proteins (eg, serum albumin).
	• Parathyroid hormone, secreted by the parathyroid gland, regulates (1) the resorption of calcium from bone (the major calcium storage site in the body); (2) reabsorption in the kidney back into circulation; and (3) increases in the activation of vitamin D3 to calcitriol.
	• Calcitriol, the active form of vitamin D3, promotes absorption of calcium from the intestines and the mobilization of calcium ions from bone matrix.
	• Hyperparathyroidism and malignancy-associated hypercalcemia are by far the most common causes of hypercalcemia, together accounting for more than 90% of cases.
	• Primary hyperparathyroidism is most often caused by a parathyroid adenoma.
	• Homeostasis of calcium concentration depends primarily on the parathyroid’s capacity to regulate calcium fluxes between the extracellular fluid space, the intestine, the kidneys, and the other bones.

Etiology and pathogenesis

Calcium regulation and balance in the human body. Calcium is transported through the bloodstream as dissolved divalent cations (Ca2+) or bound to proteins (eg, serum albumin). Calcium levels are tightly regulated.

Calcium regulation

Calcium is transported through the bloodstream as dissolved divalent cations (Ca2+) or bound to proteins (eg, serum albumin). Calcium levels are tightly regulated. Parathyroid hormone, secreted by the parathyroid gland, regulates ...
Calcium balance in the human body

The movement of calcium ions from the plasma (central square) to and from various body compartments. The sizes of the red arrows are roughly in proportion to the quantities moved in and out of the plasma per day. The influence of ...

The parathyroid gland. Although the number varies, there are usually four parathyroid glands, two on each side. The parathyroid glands are usually located on the posterior surface of the thyroid gland. The position of the parathyroid glands varies considerably. Most (71%) are located at the level of the middle or lower third of the thyroid gland, some (6%) are located at the level of the upper third of the thyroid gland, and the rest are located away from the thyroid gland, even into the mediastinum (125).

Parathyroid glands typical location (anterior-posterior view)

The parathyroid glands are located usually on the posterior surface of the thyroid gland. Although the number varies, there are usually four parathyroid glands, two on each side. (Courtesy of Wikimedia Commons. Creative Commons...
Parathyroid glands typical location (lateral view)

The parathyroid glands are located usually on the posterior surface of the thyroid gland. Although the number varies, there are usually four parathyroid glands, two on each side. (Courtesy of Wikimedia Commons. Creative Commons...
Parathyroid glands to thyroid gland relationship

The parathyroid glands, and their relationship to the thyroid gland, the three laryngeal nerves, and the inferior thyroid artery (from behind). The original image has been modified by coloring the parathyroid glands purple for eas...
Parathyroid glands (range in position)

This shows a composite of the positions of the parathyroid glands found in 25 cadavers in relation to the thyroid gland and trachea. The thyroid gland is illustrated as transparent so the parathyroid gland positions can be seen. T...

Like all endocrine glands, the parathyroid gland has a capsule and is well vascularized. There are two main cell types: principal (chief) cells and oxyphil cells. Principal (chief) cells are the predominant cell type. Principal cells have clear-cut cell outlines, and an eosinophilic cytoplasm containing lipofuscin pigment granules and moderate amounts of glycogen. Principal cells produce parathyroid hormone. Less common are oxyphil cells, which are larger than principal cells, and have light hyperchromatic to eosinophilic cytoplasmic staining and an abundant amount of cytoplasm. Oxyphil cells also secrete parathyroid hormone. Adipose tissue is frequently found in this gland in older individuals.

Parathyroid gland histology (low magnification)

Low-magnification micrograph of the parathyroid gland. Hematoxylin and eosin stain. The predominant cell type is the chief cell, with its intense hyperchromatic to eosinophilic cytoplasmic staining; chief cells manufacture parathy...
Parathyroid gland histology (intermediate magnification)

Intermediate-magnification micrograph of the parathyroid gland. Hematoxylin and eosin stain. (Courtesy of Wikimedia Commons. Creative Commons Attribution-Share Alike 3.0 Unported.)
Parathyroid gland histology (high magnification)

High-magnification micrograph of the parathyroid gland. Hematoxylin and eosin stain. (Courtesy of Wikimedia Commons. Creative Commons Attribution-Share Alike 3.0 Unported.)

Disorders associated with hypercalcemia. A broad range of disorders may lead to hypercalcemia (239; 63; 138; 203; 236). Primary hyperparathyroidism and malignancy-associated hypercalcemia are by far the most common causes of hypercalcemia, together accounting for more than 90% of cases (203; 250).

Parathyroid adenoma (low magnification)

Low-magnification micrograph of the parathyroid adenoma (left side). Hematoxylin and eosin stain. Parathyroid adenomas as small, solitary, clearly demarcated nodules within the parathyroid gland. They consist of a single cell popu...
Parathyroid adenoma (intermediate magnification)

Intermediate-magnification micrograph of the parathyroid adenoma (left side). Hematoxylin and eosin stain. In this case, normal parathyroid gland with prominent adipose tissue is seen on the right side of the image. (Courtesy of W...
Parathyroid adenoma (high magnification)

High-magnification micrograph of the parathyroid adenoma (left side). Hematoxylin and eosin stain. In this case, normal parathyroid gland with prominent adipose tissue is seen on the right side of the image. (Courtesy of Wikimedia...
Parathyroid hyperplasia (low magnification)

(Courtesy of Wikimedia Commons. Creative Commons Attribution-Share Alike 3.0 Unported.)
Parathyroid hyperplasia (intermediate magnification)

(Courtesy of Wikimedia Commons. Creative Commons Attribution-Share Alike 3.0 Unported.)
Parathyroid hyperplasia (high magnification)

(Courtesy of Wikimedia Commons. Creative Commons Attribution-Share Alike 3.0 Unported.)

Primary hyperparathyroidism (63; 189; 44)
	• Primary hyperparathyroidism is most common in patients older than 40 years, with an average age of about 55 years, and women are two to three times more likely to be affected than men. Primary hyperparathyroidism is rare in childhood.
	• Primary hyperparathyroidism is most often caused by a parathyroid adenoma, a benign tumor in a single parathyroid gland (80% to 85% of cases), or parathyroid hyperplasia, an enlargement of all four parathyroid glands (15% to 20% of cases), and rarely by parathyroid carcinoma (less than 0.1% of cases) or a multiple endocrine neoplasia syndrome.
	• Parathyroid hyperplasia may be sporadic or occur in the multiple endocrine neoplasia syndromes with pheochromocytoma, islet cell tumors, pituitary tumors, or medullary carcinoma of the thyroid.
	• A significant proportion of patients with hyperparathyroidism do not undergo appropriate evaluation and surgical referral. In a large series of 10,432 patients with hypercalcemia, only 31% had parathyroid hormone levels measured and 28% had a documented diagnosis of hypercalcemia in the medical record; of those with classic hyperparathyroidism only 22% had a surgical referral (27).
	• End-organ damage develops before or within 5 years of diagnosis for about two thirds (62% in one study) of patients (25).
	• Hyperparathyroidism-induced hypercalcemic crisis is a rare presentation of primary hyperparathyroidism (177).
Malignancy-associated hypercalcemia (206; 253; 67; 170; 229; 209; 242; 156; 102; 105; 161; 199; 202; 21).
	• Malignancy-associated hypercalcemia is the most common cause of non-parathyroid hypercalcemia (106).
	• Malignancy-associated hypercalcemia is a common complication, occurring in 10% to 30% of patients with cancer (253; 170; 229; 105).
	• Patients with malignancy-associated hypercalcemia almost always have advanced clinically evident disease.
	• Production of humoral factors by the primary tumor is collectively known as humoral hypercalcemia of malignancy and is the mechanism responsible for 80% of cases of malignancy-associated hypercalcemia (67).
	• The malignancies that are most frequently associated with humoral hypercalcemia of malignancy are hematological malignancies (eg, multiple myeloma, non-Hodgkin lymphoma, leukemias) and solid cancers (particularly renal, breast, ovarian, and endometrial carcinomas as well as squamous cell carcinomas of the lung, head and neck, or esophagus) (253; 24). In rare cases, lymphoma may present with hypercalcemia, and CT is less sensitive for lymphoma than for most solid tumors, so the diagnosis may be missed or delayed (21).
	• Humoral hypercalcemia of malignancy is usually due to secretion of parathyroid hormone-related protein by malignant tumors, but other humoral factors may be involved in rare cases (eg, tumor production of 1,25(OH)2D or parathyroid hormone) (256; 67; 209; 242; 105; 161; 202; 107). Parathyroid hormone-related protein is encoded by a separate gene (cytogenetic location: 12p11.22), but it shares sequence homology with the amino-terminal domain of parathyroid hormone (cytogenetic location: 11p15.3); this allows parathyroid hormone-related protein to cross-react at a common G protein receptor, the type 1 PTH/PTHrP receptor (PTHR1), resulting in similar skeletal effects and effects on calcium and phosphorus metabolism to that produced by parathyroid hormone (106). Hypercalcemia with concomitant elevation of both serum parathyroid hormone and parathyroid-related protein levels has been reported in a patient with advanced gastric carcinoma and multiple liver metastases (209). Severe hypercalcemia with concomitant elevation of both PTHrP and 1,25(OH)2D has been reported in a patient with non-Hodgkin lymphoma that expressed both PTHrP and CYP27B1 (this enzyme carries out the second of two reactions to convert vitamin D to its active form, 1,25-dihydroxyvitamin D3, which is also known as calcitriol) (107).
	• Local osteolytic hypercalcemia is due to skeletal invasion by malignant cells, as in multiple myeloma (which makes osteoclast activating factor that stimulates osteoclasts to resorb bone), breast or lung cancer metastatic to bone, lymphoma, and occasionally other malignancies (eg, acute lymphoblastic leukemia) (156). This is the mechanism responsible for 20% of cases of malignancy-associated hypercalcemia (67).
	• Absorptive hypercalcemia is due to excess 1,25(OH)2D production by malignancies (eg, lymphoma) (229; 199).
	• Hypercalcemia in patients with malignancies can also occur to nonmalignancy-related causes (105).
Granulomatous disorders (244; 152; 57; 237; 81)
	• A wide variety of granulomatous diseases cause hypercalcemia (246) due to enhanced extra-renal conversion of 25-hydroxy vitamin D to 1,25(OH)2D by activated macrophages within the granulomas.
	• Sarcoidosis is the granulomatous disorder most commonly associated with hypercalcemia (204; 23; 129; 198). The incidence of hypercalcemia in sarcoidosis ranges from 10% to 20%, but over 40% have hypercalciuria, often with nephrolithiasis. It may present as hypercalcemia without evident systemic manifestations.
	• Other granulomatous causes of hypercalcemia include berylliosis, mycobacteria infections (tuberculosis and granulomatous leprosy), fungal infections (histoplasmosis, blastomycosis, and coccidiomycosis), Wegener granulomatosis, foreign body granulomas, and eosinophilic granuloma.
	• Rare cases of hypercalcemia in granulomatous disorders are not explained by elevated levels of vitamin D or its metabolites (246).
Endocrine disorders (other than hyperparathyroidism)
	• Hyperthyroidism, which is associated with both increased bone resorption and increased bone turnover.
	• Addisonian crisis due to primary adrenal insufficiency is a rare cause of hypercalcemia that resolves with glucocorticoid treatment (205; 250)
	• Pheochromocytoma may be part of a multiple endocrine neoplasia syndrome, or hypercalcemia may result from production of parathyroid hormone-related protein by the pheochromocytoma (255; 250).
	• Pancreatic islet tumors that secrete vasoactive intestinal polypeptide (250). These tumors are associated with the watery diarrhea hypokalemia achlorhydria syndrome, also called pancreatic cholera (51).
	• Acromegaly may be a cause of 1,25(OH)2D-dependent hypercalcemia (241).
	• Familial hypocalciuric hypercalcemia ("familial benign hypocalciuric hypercalcemia") resembles primary hyperparathyroidism but is relatively benign in comparison: the hypercalcemia is usually asymptomatic (189; 178; 267; 90; 245; 201; 188; 258; 94). Familial hypocalciuric hypercalcemia is generally transmitted as an autosomal dominant disorder (178; 201). Most cases are caused by a loss of function mutations in the CaSR gene, which encodes a calcium-sensing receptor that is expressed in parathyroid and kidney tissue (94). The perceived lack of calcium levels by the parathyroid glands results in high levels of parathyroid hormone secretion and, therefore, hypercalcemia. The diagnosis can be confirmed by genetic testing for a mutation in the gene encoding the calcium-sensing receptor (90). Homozygous mutations in CaSR may lead to life-threatening forms of neonatal severe hyperparathyroidism. Transient neonatal hyperparathyroidism may occur in affected neonates if the mutation is paternally inherited (130).
	• The mitochondrial enzyme 1,25-dihydroxyvitamin D3 24-hydroxylase, a member of the cytochrome P450 superfamily of enzymes, is encoded by the CYP24A1 gene. Mutations in CYP24A1 may cause failure to metabolize 1,25-dihydroxyvitamin D, with resultant chronic hypercalcemia, hypercalciuria, or nephrolithiasis (139; 55; 227; 224). Pregnant women with a CYP24A1 gene mutation are at increased risk of hypercalcemia (due to upregulation of calcitriol) and fetal demise (55; 227; 224). Pathogenic mutations of CYP24A1 should be considered in the differential diagnosis of hypercalcemia with low parathyroid hormone concentrations, particularly if there is a reduced ratio of 24,25-dihydroxyvitamin D to 25-hydroxyvitamin D (224). Diagnosis is confirmed by genetic analyses (224). Monoallelic carriers have significant rates of nephrolithiasis (19%), nephrocalcinosis (5%), and symptomatic hypercalcemia (6%) (55). Strictly avoiding vitamin D supplementation may be effective in preventing or reducing the degree of hypercalcemia in affected individuals (227; 224).
	• Malignancies and systemic lupus erythematosus can be associated with elevated parathyroid hormone-related protein (256; 67; 209; 242; 105; 161; 280; 202).
Medications
		• Recombinant human PTH (167). Transient hypercalcemia can occur in patients with hypoparathyroidism receiving recombinant human PTH because of overtreatment, usually during acute illness (167).
	• Vitamin A intoxication (266; 232; 47), usually with doses over 50,000 units daily. Vitamin A is provided in supplements and animal sources (animal liver, fish liver oil, dairy, and eggs).
	• Vitamin D intoxication in health faddists or as a complication of treatment, usually with high-dose ergocalciferol that is stored in fat depots for months (51; 112; 183; 222; 260; 73; 151; 100; 167; 237; 53). Vitamin-D toxicity is the second most common cause of hypercalcemia after primary hyperparathyroidism (151). In a systematic review of vitamin D toxicity from overcorrection of vitamin D deficiency, patients presented with serum 25-hydroxy vitamin D concentrations ranging between 150 and 1220 ng/mL and serum calcium concentrations between 11.1 and 23.1 mg/dL (100). Most of the reported patients showed symptoms of vitamin D toxicity including vomiting, dehydration, pain, and loss of appetite (100). The underlying causes of overcorrection of vitamin D deficiency included manufacturing errors and overdosing by patients or prescribers (100). In the elderly population with hypervitaminosis D and vitamin D intoxication, most patients were normocalcemic, but severe hypercalcemia is also reported, which can be life-threatening and result in death (53).
	• Thiazide diuretics (52; 80; 167). Thiazide-induced hypercalcemia is usually attributed to enhanced renal calcium reabsorption by increasing Na/Ca exchange in the distal convoluted tubule (eg, changing preexistent asymptomatic normocalcemic or intermittently hypercalcemic hyperparathyroidism into the classic hypercalcemic hyperparathyroidism) (167). The hypercalcemic effect of thiazides also occurs in anephric patients, so nonrenal mechanisms contribute to the development of thiazide-associated hypercalcemia (157).
	• Lithium carbonate (171; 194). Lithium causes hypercalcemia mainly by drug-induced hyperparathyroidism (167).
	• Theophylline preparations (usually seen following "bolus" administration of aminophylline in emergency room settings) (191)
	• Estrogen and antiestrogen use in women with breast cancer and skeletal metastases (169)
	• Corticosteroid therapy (214)
	• Foscarnet (103; 28; 225; 106)
	• Milk-alkali syndrome is characterized by the triad of hypercalcemia, renal insufficiency, and metabolic alkalosis that results from overconsumption of calcium-containing products (35; 155; 128; 208). During pregnancy there is a physiological increase in calcium absorption, and in this setting milk-alkali syndrome can be life-threatening (155).
Acute and chronic renal failure
	• Causes of hypercalcemia in acute and chronic renal failure include vitamin D therapy, calcium carbonate use, aluminum intoxication, and severe secondary or tertiary hyperparathyroidism (52; 189; 93). Hypercalcemia may occur rarely during the recovery phase of acute renal failure (236).
	• In patients with end-stage renal disease, neither uncorrected nor albumin corrected total serum calcium levels are reliable indicators or ionized calcium levels (213). Most patients with end-stage renal disease and elevated ionized calcium levels are falsely categorized as normocalcemic using conventional total serum calcium assays (213). Such “hidden hypercalcemia” in patients with end-stage renal disease is associated with a significantly higher risk of death (213).
Advanced chronic liver disease (160)
	• This may be transient and may not require treatment (160).
Immobilization (254; 64; 168; 54; 128; 196)
	• Severe hypercalcemia may result from immobilization in the setting of paraplegia, quadriplegia, extensive skeletal fractures, or prolonged enforced bedrest.
	• Immobilization hypercalcemia usually occurs with immobilization in the setting of increased skeletal turnover (eg, children or adolescents, Paget disease of the bone, primary or secondary hyperparathyroidism, cancer) (254; 64; 168; 128).
Protein abnormalities
	• Hyperalbuminemia. Approximately 50% of circulating calcium is bound to albumin. Disorders that raise or lower albumin concentrations cause corresponding alterations in total but not ionized serum calcium. This is a formula to correct for changes in albumin concentration: corrected calcium = serum calcium + 0.8* (normal albumin – patient albumin).
	• Calcium binding immunoglobulins in patients with multiple myeloma. Rarely, immunoglobulins are produced that specifically bind calcium and lead to asymptomatic elevation in total but not ionized serum calcium (195).
Infantile hypercalcemia
	• Williams syndrome (or Williams-Beuren syndrome, OMIM #194050). Infantile hypercalcemia, usually mild and transient, is associated with multiple congenital developmental defects, including mental retardation, gregariousness, profound visuo-spatial impairment, “elfin” facies, a low nasal bridge, and supravalvular aortic stenosis (239; 236). Other findings can include chronic serous otitis media, hyperacusis, and obstructive sleep apnea (200). It is caused by a deletion of about 26 genes from the long arm of chromosome 7 (7q11.23). The syndrome was described in 1961 by New Zealand cardiologist John C P Williams (b 1922). The hypercalcemia associated with Williams syndrome typically, but not invariably, resolves by the first year (126). The cause of the hypercalcemia in Williams syndrome is still unclear (74; 101; 230; 158; 223; 174).
	• Idiopathic infantile hypercalcemia (OMIM #143880). Idiopathic infantile hypercalcemia (oddly, the "idiopathic" persists even though responsible mutations in several genes have been identified) is a rare inborn form of severe hypersensitivity to vitamin D, which tends to abate by 1 year of age (192; 277; 233; 238; 237; 78; 59; 84; 98; 251; 145; 85; 263; 66; 173; 172; 281). Infantile hypercalcemia1 (HCINF1) is caused by a CYP24A1 mutation (cytochrome p450, family 24, subfamily a, polypeptide 1) on chromosome 20q13.2, resulting in slow inactivation of 1,25-dihydroxy-vitamin D3 with subsequent hypercalcemia. Common signs include lethargy, psychomotor retardation, failure to thrive, muscle hypotonia, dehydration, constipation, and nephrocalcinosis. Laboratory investigations show hypercalcemia, elevated vitamin D levels, hypercalciuria, and low parathyroid hormone levels (281). Infantile hypercalcemia-2 (HCINF2) is caused by a homozygous or compound heterozygous mutation in the SLC34A1 gene (solute carrier family 34; type II sodium/phosphate cotransporter; OMIM 182309) on chromosome 5q35. Infantile hypercalcemia with nephrocalcinosis can also be caused by a heterozygous mutation in the SLC34A3 gene (solute carrier family 34; sodium/phosphate cotransporter) on chromosome 9q34.3 (173). Biallelic mutations in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria and also, rarely, with intermittent hypercalcemia (77; 259). The clinical presentation of mild so-called "idiopathic" infantile hypercalcemia is variable as is the underlying genetic cause (173; 172). Dietary calcium and vitamin D restriction does not consistently normalize elevated 1,25(OH)2D concentrations or uniformly prevent worsening of renal calcification (172). The milder form of idiopathic infantile hypercalcemia has a distinctive vitamin D metabolite profile and is primarily associated with heterozygous SLC34A1 and SLC34A3 variants, whereas biallelic variants in the CYP24A1 or SLC34A1 genes are associated with severe idiopathic infantile hypercalcemia (173).
	• Benign familial hypercalciuric hypercalcemia (251). At least three types of benign familial hypercalciuric hypercalcemia have been identified: type I with autosomal dominant inheritance due to heterozygous loss-of-function mutations in the CASR gene (601199), which encodes the calcium-sensing receptor, on chromosome 3q13.3-q21.1, OMIM #145980; type II with autosomal dominant inheritance due to heterozygous mutations in the GNA11 gene (139313) on chromosome 19p13.3, OMIM #145981; and type III with autosomal dominant inheritance due to heterozygous mutations in the AP2S1 gene (602242) on chromosome 19p13.32, OMIM # 600740.
	• Iatrogenic hypervitaminosis D (146; 251).
	• Subcutaneous fat necrosis (29; 272; 275; 20; 82; 45; 179; 283; 01; 251).

Genetic changes associated with familial hypocalciuric hypercalcemia

In familial hypocalciuric hypercalcemia (FHH) types 1-3, inactivating mutations in CaSR, GNA11, or AP2S1 lead to loss of function of signaling through the CaSR pathway and, therefore, require higher extracellular calcium concen...

Primary hyperparathyroidism is most often caused by a parathyroid adenoma.

Parathyroid adenoma

Parathyroid glands in a patient with hyperparathyroidism caused by a parathyroid adenoma. (Source Bruce Blaum.)

Homeostasis of calcium concentration depends primarily on the parathyroid’s capacity to regulate calcium fluxes between the extracellular fluid space, the intestine, the kidneys, and the other bones (135). Parathyroid hormone induces renal calcium reabsorption in the distal tubule, activates osteoclastic bone resorption, and stimulates the conversion of vitamin D precursors to the active form of vitamin D [1,25(OH)2D], which in turn increases intestinal calcium absorption. In hypercalcemia due to hyperparathyroidism, the problem is an excess secretion of parathyroid hormone with otherwise intact homeostatic control, resulting in an elevated but relatively stable concentration of calcium (so-called equilibrium hypercalcemia) (88). In hypercalcemia due to other causes, compensatory mechanisms ultimately fail, despite appropriate suppression of parathyroid hormone. Typically, one of the central features of this decompensation, occurring in the more advanced stages of primary hyperparathyroidism as well, relates to the hypercalciuria-induced diuresis that leads to volume depletion and decreased glomerular filtration rate. The resulting decreased delivery of calcium and increased tubular reabsorption (which may already be increased if the parathyroid hormone or parathyroid-related protein is elevated) diminishes the kidney’s capacity to counteract the underlying problem (88; 52).

Calcium ions from the serum diffuse easily across the blood-brain barrier, and levels can directly correlate with calcium levels in both cerebrospinal fluid and brain parenchyma (142). Nevertheless, the precise mechanisms by which hypercalcemia causes neurologic symptoms remain unclear.

Differential diagnosis

Confusing conditions

The symptoms of hypercalcemia are nonspecific, and especially in the setting of malignancy-associated hypercalcemia the symptoms caused by hypercalcemia may be difficult to differentiate from tumor- or treatment-related symptoms (170).

Hypercalcemia should be considered in the differential diagnosis of encephalopathy, generalized weakness, and posterior reversible leukoencephalopathy syndrome. The likelihood of hypercalcemia being present increase if commonly associated symptoms are present, such as dehydration, fatigue, weight loss, anorexia, constipation, nausea, vomiting, or abdominal pain. Note that hypermagnesemia may closely mimic the effects of hypercalcemia.

An important consideration in the differential diagnosis of patients with a malignancy and a clinical picture of encephalopathy is tumor lysis syndrome. This oncologic emergency occurs most commonly after the initiation of cytotoxic chemotherapy in patients with high-grade lymphomas or other hematologic malignancies and rarely with solid tumors. Massive cell lysis results in multiple metabolic derangements, including elevated serum uric acid 8.0 mg/dL or greater, hyperkalemia 6.0 mmol/L or greater, hyperphosphatemia 6.5 mg/dL or greater, and hypocalcemia 7.0 mg/dL or less. Clinical presentation can include encephalopathy, nausea, vomiting, anorexia, heart failure, cardiac dysrhythmias, seizures, tetany, and death (69). In contrast to malignancy-associated hypercalcemia, patients with tumor lysis syndrome are more likely to suffer diarrhea than constipation.

Associated or underlying disorders

The most common causes of hypercalcemia are primary hyperparathyroidism and malignancy, with primary hyperparathyroidism being the most common cause in ambulatory patients, and malignancy-related hypercalcemia being the most common cause among hospitalized patients. A history of hypercalcemia for over a year, in the absence of known malignancy, weight loss, and other systemic signs and symptoms, generally excludes malignancy-associated hypercalcemia. Less common causes of hypercalcemia include, for example, endocrine disorders (the most common cause in this group being hyperthyroidism), granulomatous disorders (the most common cause in this group being sarcoidosis), medications (especially thiazine diuretics, vitamin D, vitamin A, calcium carbonate, and lithium), acute and chronic renal failure, and immobilization (239).

The differential diagnosis of infantile hypercalcemia includes idiopathic infantile hypercalcemia (OMIM #143880), benign familial hypercalciuric hypercalcemia (types I-III), Williams syndrome (or Williams-Beuren syndrome, OMIM #194050), iatrogenic hypervitaminosis D, neonatal hyperparathyroidism, primary hyperparathyroidism, malignancy, granulomatous disease, Jansen metaphyseal dysplasia, and subcutaneous fat necrosis (251).

Diagnostic workup

	• In most clinical circumstances, total serum calcium levels accurately reflect ionized calcium levels.
	• Hypoalbuminemia and end-stage renal disease are two common situations where total serum calcium levels may be misleading.
	• Recognizing that all calcium in the body is ionized, the term “ionized calcium” refers to the free ionic fraction that is physiologically active in blood.
	• About half of the calcium circulating in the blood is protein bound. Ninety percent of protein-bound calcium is linked to albumin, whereas the remaining 10% is bound to a variety of globulins.
	• In patients with end-stage renal disease, neither uncorrected nor albumin-corrected total serum calcium levels are reliable indicators of ionized calcium levels.
	• When the cause of hypercalcemia is not immediately obvious, careful history taking, with particular attention to medication use, will sometimes suggest the underlying problem.
	• Appropriate initial laboratory testing for hypercalcemia in adults generally includes serum total and ionized calcium, magnesium, albumin, phosphate, alkaline phosphatase, creatinine, and parathyroid hormone.
	• The principal ECG finding in hypercalcemia is a short QT interval, but EKG changes may mimic an acute myocardial infarction, and in severe hypercalcemia an Osborn wave (or J wave, ie, notching of the terminal QRS complex) may be present, mimicking the EKG findings in hypothermia.
	• In hyperparathyroidism, x-rays may show evidence of a moth-eaten appearance to the bones, so-called brown tumors, and fragility fractures.
	• EEG abnormalities associated with hypercalcemic encephalopathy include excess theta activity, delta and theta slowing, bursts of 1.5 to 2 Hz intermittent rhythmic delta activity superimposed on low-voltage background activity, and diffuse but predominantly occipital spike-slow-wave complexes.

Laboratory testing. In most clinical circumstances, total serum calcium levels accurately reflect ionized calcium levels. However, hypoalbuminemia and end-stage renal disease are two common situations where total serum calcium levels may be misleading (213).

The term “ionized calcium” refers to the free ionic fraction that is physiologically active in blood. Ionized calcium competes with hydrogen ions to bind to negatively charged sites on albumin and other calcium-binding proteins. About half of the calcium circulating in the blood is protein bound. Ninety percent of protein-bound calcium is linked to albumin, whereas the remaining 10% is bound to a variety of globulins. There are 12 potential binding sites on each albumin molecule, but only about 10% to 15% are utilized under normal conditions. Therefore, each 1 g/dL reduction in the serum albumin concentration lowers total calcium concentration by approximately 0.8 mg/dL (0.2 mmol/L) without affecting the ionized calcium concentration and, consequently, without producing any symptoms or signs of hypocalcemia.

Elevated calcium levels can be classified by severity (270; 231). Note that there are minor variations in the thresholds for these categories in different authoritative reports.

	• Mild hypercalcemia is defined as an elevated total calcium less than 12 mg/dL (< 3 mmol/L) or elevated ionized calcium less than 8.0 mg/dL (< 2.0 mmol/L).
	• Moderate hypercalcemia is defined as total calcium 12 to 13.9 mg/dl (3.0 to 3.5 mmol/L) or ionized calcium of 8.0 to 9.9 mg/dL (2.0 to 2.5 mmol/L)
	• Severe hypercalcemia is defined as total calcium 14 mg/dL or greater (≥ 3.5 mmol/L) or ionized calcium 10 mg/dL or greater (≥ 2.5 mmol/L)

In patients with end-stage renal disease, neither uncorrected nor albumin-corrected total serum calcium levels are reliable indicators or ionized calcium levels (213). Most patients with end-stage renal disease and elevated ionized calcium levels are falsely categorized as normocalcemic using conventional total serum calcium assays (213). Such “hidden hypercalcemia” in patients with end-stage renal disease is associated with a significantly higher risk of death (213).

The most important initial test to evaluate hypercalcemia in a person without known metastatic cancer is a serum intact parathyroid hormone (PTH), which distinguishes PTH-dependent from PTH-independent causes (270).

Elevated PTH may occur with primary, secondary, or tertiary forms of hyperparathyroidism (Table 1). Normally, PTH release is triggered by low calcium or high phosphate levels. PTH has several actions: (1) it stimulates bone resorption through the action of osteoclasts, increasing calcium and phosphate levels; (2) it acts on the kidney to increase calcium resorption from the distal convoluted tubule and decrease phosphate resorption; and (3) it acts on an enzyme in the kidneys (1-alpha-hydroxylase) to convert 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D, which then targets the gut to increase calcium and phosphate absorption.

Control of parathyroid hormone synthesis or secretion

Parathyroid hormone (PTH) synthesis or secretion can be decreased in the chief cell of the parathyroid gland by different mechanisms: (1) increased extracellular calcium concentrations by activation of the calcium-sensing recep...
Physiology of parathyroid hormone

Abbreviations: 1,25-DOH-Vit-D: 1,25 dihydroxy hydroxycholecalciferol; 25-OH-Vit-D: 25 monohydroxy hydroxycholecalciferol; CKD: chronic kidney disease; FGF: fibroblast factor; PTH: parathyroid hormone; Vit D: vitamin D. (Source:...

The net effect of PTH is to increase calcium levels and decrease phosphate levels. Secondary and tertiary forms of hyperparathyroidism are most common with chronic kidney disease. Secondary hyperparathyroidism (SHPT) is an increased secretion of PTH due to parathyroid hyperplasia caused by triggers, such as hypocalcemia, hyperphosphatemia, or decreased active vitamin D (248; 207). In secondary hyperparathyroidism due to advanced chronic kidney disease, the kidney has trouble getting rid of phosphates and difficulty converting vitamin D to its active form (115).

Pathophysiology of secondary hyperparathyroidism

Abbreviations: 1,25DHD: 1,25 dihydroxy vitamin D; Ca-R: calcium receptor; CKD: chronic kidney disease; FGF-23: fibroblast growth factor-23; FGFR: fibroblast growth factor receptor; iPh: inorganic phosphate; PTH: parathyroid hor...

The resultant rising serum phosphate binds serum calcium, so serum calcium goes down, stimulating the parathyroid gland to secrete PTH. PTH then stimulates the release of calcium (and phosphate) from bones in an indirect process through osteoclasts; it also stimulates the kidney to activate vitamin D to facilitate gastrointestinal absorption of calcium (although chronic kidney disease also reduces the synthesis of activated vitamin D). Another cause of secondary hyperparathyroidism is vitamin D deficiency. Diagnosis of secondary hyperparathyroidism can be made with high confidence by documenting an increased serum PTH level with an elevated phosphate level, a low or normal calcium level, and an underlying renal failure or vitamin D deficiency (276). Given the pathophysiology of secondary hyperparathyroidism, the treatment involves optimizing chronic kidney disease, a low-phosphate diet, phosphate binders (which bind phosphate in the gut and thereby decrease phosphate absorption), and ergocalciferol (vitamin D2) (Vestergaard and Thomsen 2011). Tertiary hyperparathyroidism develops as a consequence of longstanding secondary hyperparathyroidism; eventually the parathyroid gland undergoes hyperplasia and begins secreting PTH irrespective of serum calcium levels (Vestergaard and Thomsen 2011; 140). The treatment of tertiary hyperparathyroidism is similar to primary hyperparathyroidism and typically involves parathyroidectomy.

Table 1. Lab Studies in Primary, Secondary, and Tertiary Hyperparathyroidism

Hyperparathyroidism	Serum calcium	Serum phosphate	PTH
Primary	H (or high N)	L*	H
Secondary	L or maybe N	H (failure of renal excretion)	H
Tertiary	H (or high N)	H or N (eg, with phosphate binders)	H
Symbols: H, high; L, low; N, normal
*PTH promotes renal excretion of phosphates (assuming normal renal function)

Rarely, endogenous antibodies can interfere with 25-hydroxy vitamin D immunoassays (36). In one case with a myeloma-related IgG monoclonal gammopathy, hypercalcemia with low parathyroid hormone levels and apparently very high 25-hydroxyvitamin D levels mimicked vitamin D intoxication (36). Alternative vitamin D assays are available, which can give correct results in these rare circumstances.

The clinical setting often dictates the extent of the diagnostic workup for hypercalcemia, as the likely etiology may be evident at the time of presentation (eg, malignancy or renal failure). When the cause is not immediately obvious, careful history taking, with particular attention to medication use, will sometimes suggest the underlying problem. Appropriate initial laboratory testing in adults generally includes serum total and ionized calcium, magnesium, albumin, phosphate, alkaline phosphatase, creatinine, and parathyroid hormone (93). The highly sensitive and specific immunoassay for parathyroid hormone offers a straightforward approach to the diagnosis of hyperparathyroidism. Assays measuring intact parathyroid hormone should be used because the results of these assays are independent of renal function. The finding of an elevated parathyroid hormone-related peptide is helpful in confirming a diagnosis of humoral malignancy-associated hypercalcemia: parathyroid hormone-related peptide acts via parathyroid hormone receptors but is not detected by parathyroid hormone assays. When these latter two tests fail to provide a diagnosis, measurement of plasma 1,25(OH)2D may be useful; an elevated level in this setting would raise the possibility, for example, of a granulomatous disorder. Diagnosis of one of the less frequent causes of hypercalcemia (eg, sarcoidosis) may require a more focused and intensive search (239).

Different causes of infantile hypercalcemia can be distinguished by blood and urine studies, and then targeted genetic studies in appropriate circumstances (251). The following blood studies are recommended: calcium, phosphate, parathyroid hormone, 25(OH)D, and 1,25(OH)2D. Urine calcium and phosphate are also recommended.

Electrocardiography. The principal ECG finding in hypercalcemia is a short QT interval, but EKG changes may mimic an acute myocardial infarction, and in severe hypercalcemia an Osborn wave (or J wave, ie, notching of the terminal QRS complex) may be present, mimicking the EKG findings in hypothermia (215).

Osborn wave

Osborn wave (J wave, ie, notching of the terminal QRS complex) on EKG, which may be seen in hypothermia and severe hypercalcemia. (Source J E Roediger. Courtesy of Wikipedia.)

Bone x-rays. In hyperparathyroidism, x-rays may show evidence of a moth-eaten appearance to the bones, so-called brown tumors, and fragility fractures.

Hand x-rays in hyperparathyroidism

X-ray of the hands showing brown tumors in a patient with hyperparathyroidism. (Contributed by Ahmed Haroud. Courtesy of Radiopaedia.org and Wikipedia.)

Parathyroid imaging. Primary hyperparathyroidism causing hypercalcemia or end-organ damage (eg, kidney stones or osteoporosis) should be treated whenever possible by parathyroidectomy. Accurate preoperative location of parathyroid adenomas is crucial for surgery planning, particularly for minimally invasive surgery. Ultrasonography is usually performed as an initial approach to localize parathyroid adenomas, followed by 99mTc-sestamibi scintigraphy with SPECT/CT or 4D-CT where feasible (162). 18F-fluorocholine positron emission tomography/computed tomography (18F-FCH PET/CT) is the most sensitive method for parathyroid adenoma detection, and it can be combined with 4D-CT to increase its diagnostic performance. Parathyroid imaging is not routinely used in secondary hyperparathyroidism because parathyroidectomy is not usually part of the management of these patients. Parathyroid imaging is used for tertiary hyperparathyroidism because total or subtotal parathyroidectomy is often performed. Because 18F-FCH PET/CT is the most sensitive modality in multigland disease, it is the preferred imaging technique in tertiary hyperparathyroidism; however, cost and availability limit its use.

Electroencephalography. EEG abnormalities associated with hypercalcemic encephalopathy include excess theta activity, delta and theta slowing, bursts of 1.5 to 2 Hz intermittent rhythmic delta activity superimposed on low-voltage background activity, and diffuse but predominantly occipital spike-slow-wave complexes (149; 228). Periodic discharges are rare in hypercalcemic encephalopathy (228). EEG abnormalities may resolve after normalization of serum calcium levels (228).

Management

	• The management of hypercalcemia depends on its severity and the nature of the underlying disorder.
	• In cases of primary hyperparathyroidism, surgery is generally indicated for all symptomatic patients and for patients with asymptomatic, mild hypercalcemia who meet certain clinical or laboratory criteria.
	• In patients with advanced incurable cancer, withholding treatment of hypercalcemia may be the most appropriate course of action.
	• Patients with mild hypercalcemia (less than 12 mg/dl) do not require emergent intervention.
	• Treatment of patients with moderate hypercalcemia (12 to 13.5 mg/dl) is guided by the clinical status of the patient.
	• In the setting of severe hypercalcemia, treatment with intravenous bisphosphonates is recommended because bisphosphonates are well tolerated and have a more prolonged effect than most other agents.
	• Calcitonin can be a useful initial adjunct for severe hypercalcemia because of its rapid onset of action.
	• Dietary calcium restriction (less than 400 mg/day) is indicated in patients with vitamin D intoxication, granulomatous disorders, milk-alkali syndrome, severe hyperparathyroidism, and in patients with lymphomas that produce 1,25(OH)2D.
	• Dialysis using a low-calcium dialysate is an effective means of lowering the serum calcium and is indicated particularly in selected patients with congestive heart failure or acute reversible renal failure.

The management of hypercalcemia depends on its severity and the nature of the underlying disorder (88; 63; 52; 136; 253; 262).

Treatment or correction of the underlying cause. Treatment or correction of the underlying cause, when possible, may be the only necessary intervention when hypercalcemia is mild. In cases of primary hyperparathyroidism, surgery is generally indicated for all symptomatic patients and for patients with asymptomatic, mild hypercalcemia who meet certain clinical or laboratory criteria (52; 265; 44; 95). Approximately 1.6% of patients with sporadic primary hyperparathyroidism eventually develop recurrence following parathyroidectomy (278). In patients with advanced incurable cancer, withholding treatment of hypercalcemia may be the most appropriate course of action.

Mild hypercalcemia (less than 12 mg/dl). Patients with mild hypercalcemia (less than 12 mg/dl) do not require emergent intervention. Instead, they should be counseled to avoid possible exacerbating factors, including excess calcium intake (more than 1000 mg/day), and alternative medications should be prescribed in place of those that can lead to hypercalcemia (ie, lithium carbonate and thiazide diuretics). Patients should also be instructed to avoid immobilization, avoid salt restriction, and maintain adequate fluid intake.

In patients older than 50 years with serum calcium levels less than 1 mg above the upper limit of normal and no evidence of skeletal or kidney disease, and no obvious known cause, observation may be appropriate (270). If mild hypercalcemia is due to primary hyperparathyroidism, parathyroidectomy may be considered depending on age, serum calcium level, and kidney or skeletal involvement (270).

Moderate hypercalcemia (12 to 13.9 mg/dl). Treatment of patients with moderate hypercalcemia (12 to 13.9 mg/dl) is guided by the clinical status of the patient. If the patient is asymptomatic, a conservative approach may be sufficient. However, if the patient is symptomatic, especially with signs of encephalopathy, then a more aggressive approach is required. The goal of therapy is alleviation of symptoms rather than rapid normalization of serum calcium.

Severe hypercalcemia (greater than 14 mg/dL). For patients with severe hypercalcemia or moderate hypercalcemia and significant clinical manifestations, the initial management entails strategies that directly lower the calcium concentration independent of the underlying cause, including measures that either restore extracellular fluid volume or increase renal calcium excretion of inhibit bone resorption.

Restore extracellular fluid volume. Because almost all patients in this setting are dehydrated, volume repletion is the essential first step toward reestablishing calcium homeostasis. Volume repletion requires careful monitoring for fluid overload, especially in this patient population that is at risk for renal and cardiac dysfunction. Hydration alone is rarely sufficient to normalize calcium levels, and additional pharmacotherapy is typically required.

Enhancing renal calcium excretion. Once extracellular fund volume has been restored, saline diuresis with normal saline infusion facilitates calcium excretion. Furosemide adds little to the effect of saline diuresis and may interfere with restoration and maintenance of adequate extracellular fluid volume.

Antiresorptive therapies. Agents that inhibit bone resorption include bisphosphonates (eg, zoledronate and pamidronate), denosumab, calcitonin, plicamycin, and gallium nitrate. Of these, bisphosphonates are the most widely used because of their relative safety and efficacy profiles (284).

In the setting of severe hypercalcemia, treatment with intravenous bisphosphonates is recommended because bisphosphonates are well tolerated and have a more prolonged effect than most other agents. An intravenous infusion of bisphosphonate pamidronate disodium (60 to 90 mg) will become effective within 48 hours, and the hypocalcemic effect peaks in 1 week and can last up to 2 weeks (212). Pamidronate is less effective in patients with humoral-related hypercalcemia (114). For this reason, zoledronic acid is often used as a first-line bisphosphonate in malignancy-associated hypercalcemia (62). It has a higher response rate in normalizing serum calcium and a more prolonged effect of up to 32 days (184). Side effects can include fever, hypocalcemia, hypophosphatemia, nausea, pruritus, and acute renal failure. Osteonecrosis, particularly of the jaw, is an infrequent but important side effect of bisphosphonate therapy that is most common in patients with malignancy-associated hypercalcemia (87). Although there may be an increased risk of atypical femoral neck fractures with prolonged use of bisphosphonates in patients with osteoporosis, this is of little relevance in the setting of malignancy-associated hypercalcemia, and the overall benefit in these patients far outweighs the minimal risk of atypical fracture (243). Available data are conflicting regarding whether chronic use of bisphosphonates is associated with increased risk of esophageal cancer, but again with the time course involved in the treatment of malignancy-associated hypercalcemia, there is little relevance in this setting (56; 109).

Subcutaneous denosumab is used for bisphosphonate-refractory hypercalcemia (eg, as a second-line therapy for hypercalcemia of malignancy) and in patients with renal failure (62; 159; 31; 262). Denosumab is a human monoclonal antibody that acts as a RANKL inhibitor, a critical mediator of bone resorption and overall bone density through its ability to stimulate osteoclast formation and activity. Denosumab binds RANKL, preventing RANKL from activating RANK, its receptor on the osteoclast surface. Osteoclast formation, function, and survival are inhibited with reduced RANK–RANKL binding, and consequently, bone resorption decreases and bone mass increases (118).

Calcitonin can be a useful initial adjunct for severe hypercalcemia because of its rapid onset of action. The addition of calcitonin will produce a rapid but mild reduction in serum calcium levels (1 to 2 mg/dl) (163); calcitonin acts primarily by decreasing bone reabsorption, but it also increases renal excretion of calcium. It is effective for up to 48 hours, but tachyphylaxis eventually develops.

Gallium nitrate and plicamycin are additional therapeutic options, though both have significant side effects (284; 75).

Treatments with restricted indications

Dietary calcium restriction. Dietary calcium restriction (less than 400 mg/day) is indicated in patients with vitamin D intoxication, granulomatous disorders, milk-alkali syndrome, severe hyperparathyroidism, and in patients with lymphomas that produce 1,25(OH)2D.

Glucocorticoids. Glucocorticoids may be useful in a select group of patients, namely those with myeloma, other hematologic malignancies, sarcoidosis, and vitamin D intoxication. Glucocorticoids act to lower serum calcium by several mechanisms, including inhibiting cytokine release, producing direct cytotoxic effects on some tumor cells, decreasing intestinal calcium absorption, and increasing urinary calcium excretion.

Dialysis. Dialysis using a low-calcium dialysate is an effective means of lowering the serum calcium and is indicated in selected patients (37). It is particularly effective in patients with congestive heart failure or acute reversible renal failure.

Special circumstances

Hypercalcemia of malignancy. As indicated earlier with general considerations on the management of hypercalcemia, the treatment of hypercalcemia of malignancy consists of enhancing renal calcium excretion (mostly through hydration with isotonic fluids) and the use of antiresorptive therapies. Intravenous zoledronic acid has often been considered the first-line treatment, with subcutaneous denosumab used for bisphosphonate-refractory hypercalcemia and in patients with renal failure (62; 133). According to Endocrine Society 2023 guidelines, in adults with hypercalcemia of malignancy, intravenous hydration and intravenous bisphosphonate or denosumab is recommended (strong recommendation) with the guidelines committee conditionally favoring denosumab over bisphosphonates, based on low-quality evidence (and the inference that denosumab is associated with greater suppression of bone turnover compared with zoledronic acid) (83; 91; 190; 240). Dialysis may be needed in some cases (37).

Conditional suggestions of the Endocrine Society based on low quality evidence include the following (83; 91):

	• In adults with severe hypercalcemia of malignancy (serum calcium level > 14 mg/ dL), consider combination therapy with calcitonin and an intravenous bisphosphonate or denosumab.
	• For refractory or recurrent hypercalcemia of malignancy despite treatment with intravenous bisphosphonate, consider the addition of denosumab.
	• For hypercalcemia due to high calcitriol levels with symptomatic or severe hypercalcemia despite glucocorticoid therapy, consider the addition of intravenous bisphosphonate or denosumab.
	• Patients with parathyroid carcinoma can be treated with calcimimetic and/or antiresorptive therapy, depending on the severity and results from initial treatment.

Hypophosphatemia. Oral phosphorus replacement should be used only in patients with phosphorus values less than 3.0 mg/dL and normal renal function to minimize the risk of ectopic soft-tissue calcification.

Immobilized patients. Mobilization is critical in reversing hypercalcemia in immobilized patients. This must include weight bearing. Passive range-of-motion exercises are inadequate.

Special considerations

Pregnancy

Although none of the common forms of hypercalcemia are epidemiologically linked with pregnancy, hypercalcemia due to any of the possible underlying disorders may first come to light during pregnancy.

Primary hyperparathyroidism. Hypercalcemic disorders in pregnant women are usually due to primary hyperparathyroidism (76). In general, in patients with primary hyperparathyroidism, parathyroidectomy is delayed until after parturition, but severe cases may warrant second trimester parathyroidectomy.

Loss-of-function mutations of the CYP24A1 gene. Loss-of-function mutations of the CYP24A1 gene cause a deficiency of the CYP24A1 enzyme, which is involved in the catabolism of 1,25-dihydroxyvitamin D₃ (calcitriol). Because pregnancy is associated with an upregulation of the active vitamin D hormone calcitriol, loss-of-function mutations of the CYP24A1 gene are likely to trigger symptomatic hypercalcemia in affected women during pregnancy (55; 224). Pathogenic mutations of CYP24A1 should be considered in the differential diagnosis of hypercalcemia with low parathyroid hormone concentrations, particularly if there is a reduced ratio of 24,25-dihydroxyvitamin D to 25-hydroxyvitamin D, or if the 1,25-dihydroxyvitamin D₃ level is elevated while the 25-hydroxyvitamin D level is still within the reference range (227; 224). Diagnosis is confirmed by genetic analyses (224). In affected women, pregnancy is associated with high rates of obstetric complications (55). Strictly avoiding vitamin D supplementation may be effective in preventing or reducing the degree of hypercalcemia (227; 224). Calcium and 25-hydroxyvitamin D levels should be monitored in routine blood tests during pregnancy (227). Hypercalcemia in a newborn should be carefully evaluated and treated as hypercalciuria can lead to nephrocalcinosis (227).

Anesthesia

General anesthesia is best avoided in patients with hypercalcemia except in emergencies because of the risk of cardiac arrhythmias.

Media

References

01: Akcay A, Akar M, Oncel MY, et al. Hypercalcemia due to subcutaneous fat necrosis in a newborn after total body cooling. Pediatr Dermatol 2013;30(1):120-3. PMID 22352980
02: Albright F. Case records of the Massachusetts General Hospital - case 27461. N Engl J Med 1941;225:789-91.
03: Albright F. A page out of the history of hyperparathyroidism. J Clin Endocrinol 1948;8(8):637-57. PMID 18877062
04: Albright F, Aub JC, Bauer W. Hyperparathyroidism: a common and polymorphic condition as illustrated by seventeen proved cases from one clinic. JAMA 1934a;102:1276-87.
05: Albright F, Baird PC, Cope O, Bloomberg E. Studies on the physiology of the parathyroid glands. IV. Renal complications of hyperparathyroidism. Am J Med Sci 1934b;187:49-65.
06: Albright F, Bauer W, Claflin D, Cockrill JR. Studies in parathyroid physiology III. The effect of phosphate inges- tion in clinical hyperparathyroidism. J Clin Invest 1932;11(2):411-35. PMID 16694050
07: Albright F, Bloomberg E, Castleman B, Churchill ED. Hypoparathyroidism due to diffuse hyperplasia of all parathyroid glands rather than adenoma of one: clinical studies on three such cases. Arch Intern Med 1934c;54:315-29.
08: Albright F, Butler AM, Bloomberg E. Rickets resistant to vitamin D therapy. Am J Dis Child 1937;54:529-47.
09: Albright F, Butler AM, Hampton AO, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pig- mentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med 1937c;216:727-46.
10: Albright F, Ellsworth R. Studies on the physiology of the parathyroid glands. I. Calcium and phosphorus studies on a case of idiopathic hypoparathyroidism. J Clin Invest 1929;7(2):183-201. PMID 16693857
11: Albright F, Forbes AP, Henneman PH. Pseudo-pseudohypoparathyroidism. Trans Assoc Am Physicians 1952;65:337-50. PMID 13005676
12: Albright F, Henneman P, Benedict PH, Forbes AP. Idiopathic hypercalciuria: a preliminary report. Proc Roy Soc Med 1953;46(12):1077-81. PMID 13120841
13: Albright F, Reifenstein EC Jr. The parathyroid glands and metabolic bone disease. Baltimore: The Williams and Wilkins Co., 1948.
14: Albright F, Sulkowitch HW. The effect of vitamin D on calcium and phosphorus metabolism: studies on four patients. J Clin Invest 1938;17(3):305-15. PMID 16694575
15: Albright F, Sulkowitch HW, Bloomberg E. Further experience in the diagnosis of hyperparathyroidism, including a discussion of cases with a minimal degree of hyperparathyroidism. Am J Med Sci 1937d;193:800-12.
16: Albright F, Sulkowitch HW, Bloomberg E. Hyperparathyroidism due to idiopathic hypertrophy (hyperplasia?) of parathyroid tissue. Arch Intern Med 1938;62:199-215.
17: Albright F, Talbot NB, et al. Carcinoma of adrenal cortex. N Engl J Med 1949;241(22):874-7, illust. PMID 15397015
18: Albright G, Burnett CH, Smith PH, Parson W. Pseudohypoparathyroidism – An example of Seabright-Bantam syndrome. Endocrinology 1942;30:922-32.
19: Almuradova E, Cicin I. Cancer-related hypercalcemia and potential treatments. Front Endocrinol (Lausanne) 2023;14:1039490. PMID 37033238
20: Alos N, Eugène D, Fillion M, Powell J, Kokta V, Chabot G. Pamidronate: treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis. Horm Res 2006;65(6):289-94. PMID 16612105
21: Altshuler E, Aryan M, King W, Otero R. Missed diagnosis of lymphoma presenting with humoral hypercalcemia of malignancy due to cessation of oncological workup after negative computed tomography scans. BMJ Case Rep 2021;14(12):e246669. PMID 34969803
22: Anonymous. Fuller Albright (1900-1969). N Engl J Med 1970;282(5):280-1. PMID 4903108
23: Arai Y, Tanaka H, Hirasawa S, et al. Sarcoidosis in a chronic dialysis patient diagnosed by sarcoidosis-related hypercalcemia with no common systemic clinical manifestations: a case report and review of the literature. Intern Med 2013;52(23):2639-44. PMID 24292755
24: Asonitis N, Angelousi A, Zafeiris C, Lambrou GI, Dontas I, Kassi E. Diagnosis, pathophysiology and management of hypercalcemia in malignancy: a review of the literature. Horm Metab Res 2019;51(12):770-8. PMID 31826272
25: Assadipour Y, Zhou H, Kuo EJ, Haigh PI, Adams AL, Yeh MW. End-organ effects of primary hyperparathyroidism: a population-based study. Surgery 2019;165(1):99-104. PMID 30420089
26: Axelrod L. Bones, stones and hormones: the contributions of Fuller Albright. N Engl J Med 1970;283(18):964-70. PMID 4919084
27: Balentine CJ, Xie R, Kirklin JK, Chen H. Failure to diagnose hyperparathyroidism in 10,432 patients with hypercalcemia: opportunities for system-level intervention to increase surgical referrals and cure. Ann Surg 2017;266(4):632-40. PMID 28678063
28: Barba R, Gómez-Rodrigo J, Marco J, Espejo M, Mena D. Transient foscarnet-induced hypercalcaemia. AIDS 1998;12(14):1930-1. PMID 9792397
29: Barltrop D. Hypercalcaemia associated with neonatal subcutaneous fat necrosis. Arch Dis Child 1963;38:516-8. PMID 14065996
30: Barr ML, Rossiter RJ. James Bertram Collip, 1892-1965. Biogr Mem Fellows R Soc 1973;19:235-67. PMID 11615724
31: Barth K, Sedivy M, Lindner G, Schwarz C. Successful treatment with denosumab for two cases with hypercalcemia due to vitamin D intoxication and associated acute kidney injury. CEN Case Rep 2022;11(1):141-5. PMID 34515963
32: Bartter FC. Fuller Albright 1900-1969. President, Endocrine Society, 1946-1947. Endocrinology 1970a;87(6):1109-12. PMID 4921560
33: Bartter FC. Fuller Albright 1900-1969, President, Endocrine Society, 1946-1947. J Clin Endocrinol Metab 1970b;31(6):607-10. PMID 4921645
34: Bauer W, Albright F, Aub JC. A case of osteitis fibrosa cystica (osteomalacia?) with evidence of hyperactivity of the parathyroid bodies. Metabolic study II. J Clin Invest 1930;8(2):229-48. PMID 16693893
35: Beall DP, Henslee HB, Webb HR, Scofield RH. Milk-alkali syndrome: a historical review and description of the modern version of the syndrome. Am J Med Sci 2006;331(5):233-42. PMID 16702792
36: Belaidi N, Georges A, Lacroix I, et al. Hypercalcemia and elevated concentration of vitamin D: a case report too easy to be true. Clin Chim Acta 2016;457:123-4. PMID 27095608
37: Bentata Y, Benabdelhak M, Haddiya I, Oulali N, Housni B. Severe hypercalcemia requiring acute hemodialysis: a retrospective cohort study with increased incidence during the Covid-19 pandemic. Am J Emerg Med 2022;51:374-7. PMID 34823193
38: Berkeley YW, Beebe SB. A contribution to the physiology and chemistry of the parathyroid glands. J Med Res 1909;20:149-57.
39: Berson SA, Yalow RS. Parathyroid hormone in plasma in adenomatous hyperparathyroidism, uremia, and bronchogenic carcinoma. Science 1966;154(3751):907-9. PMID 4975444
40: Berson SA, Yalow RS. Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab 1968;28(7):1037-47. PMID 5660255
41: Berson SA, Yalow RS. Clinical applications of radioimmunoassay of plasma parathyroid hormone. Am J Med 1971;50(5):623-9. PMID 4930270
42: Berson SA, Yalow RS, Aurbach GD, Potts JT. Immunoassay of bovine and human parathyroid hormone. Proc Natl Acad Sci U S A 1963;49(5):613-7. PMID 16591075
43: Bett WR. Sir Richard Owen; 1804-92. Ann R Coll Surg Engl 1954;15(4):272-3. PMID 13208103
44: Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005;257(1):6-17. PMID 15606372
45: Bonnemains L, Rouleau S, Sing G, Bouderlique C, Coutant R. Severe neonatal hypercalcemia caused by subcutaneous fat necrosis without any apparent cutaneous lesion. Eur J Pediatr 2008;167(12):1459-61. PMID 18365253
46: Boonstra CE, Jackson CE. Hyperparathyroidism detected by routine serum calcium analysis: prevalence in a clinic population. Ann Intern Med 1965;63:468-74. PMID 14327509
47: Borgan SM, Khan LZ, Makin V. Hypercalcemia and vitamin A: a vitamin to keep in mind. Cleve Clin J Med 2022;89(2):99-105. PMID 35105698
48: Breimer L, Sourander P. The discovery of the parathyroid glands in 1880: triumph and tragedy of Ivar Sandström. Bull Hist Med 1981;55(4):558-63. PMID 7039741
49: Browne JS, Denstedt OF. James Bertram Collip (1892-1965). Endocrinology 1966;79(2):225-8. PMID 5331934
50: Burnett CH, Commons RR, Albright F, Howard JE. Hypercalcemia without hypercalciuria or hypophosphatemia, calcinosis and renal insufficiency. N Engl J Med 1949;240:787-94.
51: Burtis WJ, Stewart AF. Non-parathyroid causes of hypercalcemia. In: Becker KL, editor. Principles and practice of endocrinology and metabolism. Philadelphia: Lippincott, 1990:437-46.
52: Bushinsky DA, Monk RD. Calcium. Lancet 1998;352:306-11. PMID 9690425
53: Calim A. Risk of hypercalcemia in the elderly patients with hypervitaminosis D and vitamin D intoxication. Clin Lab 2023;69(3). PMID 36912306
54: Cano-Torres EA, González-Cantú A, Hinojosa-Garza G, Castilleja-Leal F. Immobilization induced hypercalcemia. Clin Cases Miner Bone Metab 2016;13(1):46-7. PMID 27252745
55: Cappellani D, Brancatella A, Morganti R, et al. Hypercalcemia due to CYP24A1 mutations: a systematic descriptive review. Eur J Endocrinol 2021;186(2):137-49. PMID 34735369
56: Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304(6):657-63. PMID 20699457
57: Caré W, Blanc E, Cournac JM, Doutrelon C, Aletti M, Lecoules S. Hypercalcemia revealing diffuse granulomatous myositis. Eur J Nucl Med Mol Imaging 2017;44(8):1413-4. PMID 28396910
58: Carney JA. The glandulae parathyroideae of Ivar Sandström. Contributions from two continents. Am J Surg Pathol 1996;20(9):1123-44. PMID 8764749
59: Castanet M, Mallet E, Kottler ML. Lightwood syndrome revisited with a novel mutation in CYP24 and vitamin D supplement recommendations. J Pediatr 2013;163(4):1208-10. PMID 23768816
60: Castilla-Guerra L, del Carmen Fernandez-Moreno M, Lopez-Chozas JM, Fernandez-Bolanos R. Electrolyte disturbances and seizures. Epilepsia 2006;47(12):1990-8. PMID 17201695
61: Cave AJE. Richard Owen and the discovery of the parathyroid glands. In: Underwood EA, editor. Science, medicine and history. Essays on the evolution of scientific thought and medical practice 2. Oxford: Oxford University Press, 1953:217-22.
62: Chakhtoura M, El-Hajj Fuleihan G. Treatment of hypercalcemia of malignancy. Endocrinol Metab Clin North Am 2021;50(4):781-92.** PMID 34774248
63: Chan FK, Koberle LM, Thys-Jacobs S, Bilezikian JP. Differential diagnosis, causes, and management of hypercalcemia. Curr Probl Surg 1997;34:445-523. PMID 9186232
64: Cheng CJ, Chou CH, Lin SH. An unrecognized cause of recurrent hypercalcemia: immobilization. South Med J 2006;99(4):371-4. PMID 16634246
65: Choudhary M, Rose F. Posterior reversible encephalopathic syndrome due to severe hypercalcemia in AIDS. Scand J Infect Dis 2005;37(6-7):524-6. PMID 16012020
66: Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016;96(1):365-408. PMID 26681795
67: Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes 2011;18(6):339-46. PMID 21897221
68: Cogan DG, Albright F, Bartter FC. Hypercalcemia and band keratopathy. Arch Opthal 1948;40:624-38.
69: Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric an adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26(16):2767-78. PMID 18509186
70: Collip JB. The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem 1925;63:395-438.
71: Collip JB, Leitch DB. A case of tetany treated with parathyrin. Can Med Assoc J 1925;15(1):59-60. PMID 20315252
72: Cope O. The story of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med 1966;274:1174-82. PMID 5327350
73: Crone M, Fogarty K. A case report: hypercalcemia due to vitamin supplementation in a patient with neurofibromatosis. Clin Cases Miner Bone Metab 2017;14(1):87-8. PMID 28740531
74: Culler FL, Jones KL, Deftos LJ. Imparied calcitonin secretion in patients with Williams syndrome. J Pediatr 1985;107(5):720-3. PMID 4056970
75: Cvitkovic F, Armand JP, Tubiana-Hulin M, et al. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 2006;12(1):47-53. PMID 16613662
76: Dandurand K, Ali DS, Khan AA. Hypercalcemia in pregnancy. Endocrinol Metab Clin North Am 2021;50(4):753-68. PMID 34774246
77: Dasgupta D, Wee MJ, Reyes M, et al. Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J Am Soc Nephrol 2014;25(10):2366-75. PMID 24700880
78: Dauber A, Nguyen TT, Sochett E, et al. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab 2012;97(2):E268-74. PMID 22112808
79: Delbridge LW, Palazzo FF. First parathyroid surgeon: Sir John Bland-Sutton and the parathyroids. ANZ J Surg 2007;77(12):1058-61. PMID 17973666
80: Desai HV, Gandhi K, Sharma M, Jennine M, Singh P, Brogan M. Thiazide-induced severe hypercalcemia: a case report and review of literature. Am J Ther 2010;17(6):e234-6. PMID 20068444
81: Di Giulio V, Fusi-Schmidhauser T, Pons M. Hypercalcemia: an underestimated value always good for a surprise. Praxis (Bern 1994) 2022;110(2):97-100. PMID 35105212
82: Diamantis S, Bastek T, Groben P, Morrell D. Subcutaneous fat necrosis in a newborn following icebag application for treatment of supraventricular tachycardia. J Perinatol 2006;26(8):518-20. PMID 16871224
83: Dickens LT, Derman B, Alexander JT. Endocrine society hypercalcemia of malignancy guidelines. JAMA Oncol 2023;9(3):430-1. PMID 36637830
84: Dinour D, Beckerman P, Ganon L, Tordjman K, Eisenstein Z, Holtzman EJ. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol 2013;190(2):552-7. PMID 23470222
85: Dinour D, Davidovits M, Aviner S, et al. Maternal and infantile hypercalcemia caused by vitamin-D-hydroxylase mutations and vitamin D intake. Pediatr Nephrol 2015;30(1):145-52. PMID 25194629
86: DuBose J, Ragsdale T, Morvant J. "Bodies so tiny": The history of parathyroid surgery. Current Surgery 2005;62(1):91-5. PMID 15708157
87: Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99. PMID 16000365
88: Edelson GW, Kleerekoper M. Hypercalcemic crisis. In: Ober KP, editor. The medical clinics of North America. Philadelphia: Saunders, 1995;79(1):79-92.
89: Eknoyan G. A history of the parathyroid glands. Am J Kidney Dis 1995;26(5):801-7. PMID 7485136
90: Eldeiry LS, Ruan DT, Brown EM, Gaglia JL, Garber JR. Primary hyperparathyroidism and familial hypocalciuric hypercalcemia: relationships and clinical implications. Endocr Pract 2012;18(3):412-7. PMID 22232026
91: El-Hajj Fuleihan G, Clines GA, et al. Treatment of hypercalcemia of malignancy in adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2023;108(3):507-28. PMID 36545746
92: Ellingson EO, Bell AW, Hanson AM. Experiments with an active extract of parathyroid. Proc Soc Exp Biol Med 1924;21:274-5.
93: Endres DB. Investigation of hypercalcemia. Clin Biochem 2012;45(12):954-63. PMID 22569596
94: English KA, Lines KE, Thakker RV. Genetics of hereditary forms of primary hyperparathyroidism. Hormones (Athens) 2024;23(1):3-14. PMID 38038882
95: Farford B, Presutti RJ, Moraghan TJ. Nonsurgical management of primary hyperparathyroidism. Mayo Clin Proc 2007;82(3):351-5. PMID 17352371
96: Felger EA, Zeiger MA. The death of an Indian Rhinoceros. World J Surg 2010;34(8):1805-10. PMID 20458582
97: Felsenfeld AJ, Levine BS, Kleeman CR. Fuller Albright and our current understanding of calcium and phosphorus regulation and primary hyperparathyroidism. Nefrologia 2011;31(3):346-57. PMID 21629339
98: Fencl F, Bláhová K, Schlingmann KP, Konrad M, Seeman T. Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene. Eur J Pediatr 2013;172(1):45-9. PMID 23001465
99: Fishman RS. The Origin of Species, Man's Place in Nature and the naming of the calcarine sulcus. Doc Ophthalmol 1997;94(1-2):101-11. PMID 9657294
100: Galior K, Grebe S, Singh R. Development of Vitamin D toxicity from overcorrection of vitamin D deficiency: a review of case reports. Nutrients 2018;10(8). PMID 30042334
101: Garabédian M, Jacqz E, Guillozo H, et al. Elevated plasma 1,25-dihydroxyvitamin D concentrations in infants with hypercalcemia and an elfin facies. N Engl J Med 1985;312(15):948-52. PMID 3838365
102: Gastanaga VM, Schwartzberg LS, Jain RK, et al. Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med 2016;5(8):2091-100. PMID 27263488
103: Gayet S, Ville E, Durand JM, et al. Foscarnet-induced hypercalcaemia in AIDS. AIDS 1997;11(8):1068-70. PMID 9223751
104: Gley E. Sur Les fonctions du corps thyroide. CR Soc Biol (Paris) 1891;43:841–7.
105: Goldner W. Cancer-related hypercalcemia. J Oncol Pract 2016;12(5):426-32. PMID 27170690
106: Goltzman D. Nonparathyroid Hypercalcemia. Front Horm Res 2019;51:77-90. PMID 30641526
107: Gonciulea AR, Wang Y, Bikle DD, Sellmeyer DE. Hypercalcemia in non-Hodgkin's lymphoma due to cosecretion of PTHrP and 1,25-dihydroxyvitamin D. Osteoporos Int 2021;32(12):2587-92. PMID 34230999
108: Grant JCB. An atlas of anatomy, by regions. Fifth ed. Baltimore: The Williams & Wilkins Co, 1962.
109: Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341:c4444. PMID 20813820
110: Gross CG. Hippocampus minor and man's place in nature: a case study in the social construction of neuroanatomy. Hippocampus 1993a;3(4):403-15. PMID 8269033
111: Gross CG. Huxley versus Owen: the hippocampus minor and evolution. Trends Neurosci 1993b;16(12):493-8. PMID 7509517
112: Guerra V, Vieira Neto OM, Laurindo AF, Paula FJ, Moysés Neto M. Hypercalcemia and renal function impairment associated with vitamin D toxicity: case report. J Bras Nefrol 2016;38(4):466-9. PMID 28001186
113: Guimard C, Batard E, Lavainne F, Trewick D. Is severe hypercalcemia immediately life-threatening? Eur J Emerg Med 2018;25(2):110-3. PMID 28338532
114: Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993;341(8861):1611-3. PMID 8099988
115: Habas E Sr, Eledrisi M, Khan F, Elzouki AY. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology and management. Cureusc 2021;13(7):e16388. PMID 34408941
116: Halsted WS. Auto- and isotransplantation, in dogs of the parathyroid glandules. J Exp Med 1909;11(1):175-99. PMID 19867240
117: Halsted WS, Evans HM. I. The parathyroid glandules. Their blood supply and their preservation in operation upon the thyroid gland. Ann Surg 1907;46(4):489-506. PMID 17862042
118: Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 2012;66(12):1139-46. PMID 22967310
119: Hanson AM. The hydrochloric X of the bovine parathyroid and its phosphotungstic acid precipitate. Mil Surgeon 1924a;54:218-19.
120: Hanson AM. Parathyroid reparations. Mil Surgeon 1924b;54:554-60.
121: Hanson AM. The standardization of parathyroid activity. JAMA 1928;90(10):747-8.
122: Hanson AM. Physiology of the parathyroid. JAMA 1935;105(2):113-4.
123: Hanson M. Notes on the hydrochloric X of the bovine parathyroid. Mil Surgeon 1923;53:434.
124: Harrison DF. Sir Richard Owen (1804-1892): comparative anatomist and palaeontologist. J Med Biogr 1993;1(3):151-4. PMID 11615256
125: Heinbach WF Jr. A study of the number and location of the parathyroid glands in man. Anatomical Record 1933;57(3):251-61.
126: Helfrich AM, Philla KQ. Late-onset hypercalcemia in Williams-Beuren syndrome: importance of early and frequent screening and intervention. J Pediatr Endocrinol Metab 2015;28(3-4):425-8. PMID 25332293
127: Henneman PH. Fuller Albright, M.D. 1900-1969. Metabolism 1970;19(3):187-8. PMID 4906362
128: Henry RK, Gafni RI. Hypercalcemia due to milk-alkali syndrome and fracture-induced immobilization in an adolescent boy with hypoparathyroidism. Horm Res Paediatr 2016;86(3):201-5. PMID 27184240
129: Hishida E, Masuda T, Akimoto T, et al. Renal failure found during the follow-up of sarcoidosis: the relevance of a delay in the diagnosis of concurrent hypercalcemia. Intern Med 2016;55(14):1893-8. PMID 27432099
130: Hoppner J, Lais S, Roll C, et al. Case report: severe neonatal course in paternally derived familial hypocalciuric hypercalcemia. Front Endocrinol (Lausanne) 2021;12:700612. PMID 34659108
131: Howard JE. Fuller Albright, 1900-1969. Trans Assoc Am Physicians 1970;83:10-1. PMID 4927286
132: Howard JE. Fuller Albright: the endocrinologists' clinical endocrinologist. Perspect Biol Med 1981;24(3):374-81. PMID 7022356
133: Hu MI. Hypercalcemia of malignancy. Endocrinol Metab Clin North Am 2021;50(4):721-8. PMID 34774243
134: Ingalls TH, Donaldson G, Albright F. The locus of action of the parathyroid hormone: experimental studies with parathyroid extract on normal and nephrectomized rats. J Clin Invest 1943;22:603-8. PMID 16695043
135: Inzucchi SE. Understanding hypercalcemia. Its metabolic basis, signs, and symptoms. Postgrad Med 2004a;115(4):69-76. PMID 15095538
136: Inzucchi SE. Management of hypercalcemia. Diagnostic workup, therapeutic options for hyperparathyroidism and other common causes. Postgrad Med 2004b;115(5):27-36. PMID 15171076
137: Jackson CE, Amato AA, Bryan WW, Wolfe GI, Sakhaee K, Barohn RJ. Primary hyperparathyroidism and ALS: is there a relation? Neurology 1998;50:1795-9. PMID 9633730
138: Jacobs TP, Bilezikian JP. Clinical review: rare causes of hypercalcemia. J Clin Endocrinol Metab 2005;90(11):6316-22. PMID 16131579
139: Jacobs TP, Kaufman M, Jones G, et al. A lifetime of hypercalcemia and hypercalciuria, finally explained. J Clin Endocrinol Metab 2014;99(3):708-12. PMID 24423361
140: Jamal SA, Miller PD. Secondary and tertiary hyperparathyroidism. J Clin Densitom 2013;16(1):64-8. PMID 23267748
141: Jarcho S. William G. MacCallum on the teaching of pathologic physiology (1906). Am J Cardiol 1974;34(5):577-9. PMID 4607355
142: Joborn C, Hetta J, Niklasson F, et al. Cerebrospinal fluid calcium, parathyroid hormone, and monoamine and purine metabolites and the blood-brain barrier function in primary hyperparathyroidism. Psychoneuroendocrinology 1991;16:311-22. PMID 1720895
143: Johansson H. Parathyroid history and the Uppsala anatomist Ivar Sandström. Med Secoli 2009;21(1):387-401. PMID 20481375
144: Johansson H. The Uppsala anatomist Ivar Sandström and the parathyroid gland. Ups J Med Sci 2015;120(2):72-7. PMID 25913489
145: Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res 2014;55(1):13-31. PMID 23564710
146: Jones KL. Williams syndrome: an historical perspective of its evolution, natural history, and etiology. Am J Med Genet Suppl 1990;6:89-96. PMID 2118785
147: Kalra S, Baruah MP, Sahay R, Sawhney K. The history of parathyroid endocrinology. Indian J Endocrinol Metab 2013;17(2):320-2. PMID 23776911
148: Kaminski HJ, Ruff RL. Endocrine myopathies. In: Engel AG, Franzini-Armstrong C, editors. Myology. 2nd ed. New York: McGraw-Hill, 1994:1726-53.
149: Kaplan PW. The EEG in metabolic encephalopathy and coma. J Clin Neurophysiol 2004;21(5):307-18. PMID 15592005
150: Kastrup O, Maschke M, Wanke I, Diener HC. Posterior reversible encephalopathy syndrome due to severe hypercalcemia. J Neurol 2002;249:1563-6. PMID 12420098
151: Khan MN, Masood MQ, Siddiqui MA, Naz S, Islam N. Vitamin-D toxicity and other non-malignant causes of hypercalcemia: a retrospective study at a tertiary care hospital in Pakistan. J Ayub Med Coll Abbottabad 2017;29(3):436-40. PMID 29076678
152: Khurana A, Cherian S, Majumder S, Nakrani R, Kowlgi GN, Dasanu CA. Retinal detachment and symptomatic hypercalcemia in a patient with sarcoidosis: unusual presentation of a granulomatous disease. Conn Med 2016;80(1):11-4. PMID 26882785
153: Kleeman CR, Levine BS, Felsenfeld AJ. Fuller albright: the consummate clinical investigator. Clin J Am Soc Nephrol 2009;4(10):1541-6. PMID 19808238
154: Kolb F. My year with Fuller Albright (1950–1951). The Endocrinologist 1999;9:127-42.
155: Kolnick L, Harris BD, Choma DP, Choma NN. Hypercalcemia in pregnancy: a case of milk-alkali syndrome. J Gen Intern Med 2011;26(8):939-42. PMID 21347876
156: Kolyva S, Efthymiadou A, Gkentzi D, Karana-Ginopoulou A, Varvarigou A. Hypercalcemia and osteolytic lesions as presenting symptoms of acute lymphoblastic leukemia in childhood. The use of zoledronic acid and review of the literature. J Pediatr Endocrinol Metab 2014;27(3-4):349-54. PMID 23934636
157: Koppel MH, Massry SG, Shinaberger JH, Hartenbower DL, Coburn JW. Thiazide-induced rise in serum calcium and magnesium in patients on maintenance hemodialysis. Ann Intern Med 1970;72(6):895-901. PMID 5448748
158: Kruse K, Pankau R, Gosch A, Wohlfahrt K. Calcium metabolism in Williams-Beuren syndrome. J Pediatr 1992;121(6):902-7. PMID 1333009
159: Kuchay MS, Mathew A, Kaur P, Mishra SK. Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism. Arch Endocrinol Metab 2021;65(5):669-73. PMID 34591412
160: Kuchay MS, Mishra SK, Farooqui KJ, Bansal B, Wasir JS, Mithal A. Hypercalcemia of advanced chronic liver disease: a forgotten clinical entity! Clin Cases Miner Bone Metab 2016;13(1):15-8. PMID 27252737
161: Kumar M, Kumar A, Kumar V, Kaur S, Maroules M. Hypercalcemia as initial presentation of metastatic adenocarcinoma of gastric origin: a case report and review of the literature. J Gastric Cancer 2016;16(3):191-4. PMID 27752397
162: Lalonde MN, Correia RD, Syktiotis GP, Schaefer N, Matter M, Prior JO. Parathyroid Imaging. Semin Nucl Med 2023;53(4):490-502. PMID 36922339
163: Lamy O, Burckhardt P. Hypercalcemia of malignancy: diagnosis and treatment options. Am J Cancer 2002;1(4):277-92.
164: Lanska DJ, Ruff RL. Myopathies and myalgias in the aged. In: Barclay L, editor. Clinical geriatric neurology. Philadelphia: Lea & Febinger Publishing Co., 1993:294-309.
165: Layzer RB. Neuromuscular manifestations of systemic disease. Philadelphia: Davis, 1985.
166: Leaf A. Fuller Albright. Biogr Mem Natl Acad Sci 1976;48:3-22. PMID 11615658
167: Lecoq AL, Livrozet M, Blanchard A, Kamenický P. Drug-related hypercalcemia. Endocrinol Metab Clin North Am 2021;50(4):743-52. PMID 34774245
168: Lee KA, Yoo WH. Immobilization hypercalcemia-associated acute renal failure in a patient with chronic tophaceous gout. Ren Fail 2009;31(9):855-7. PMID 19925296
169: Legha SS, Powell K, Buzdar AU, Blumen-Schein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer 1981;47:2803-6. PMID 7260871
170: Legrand SB. Modern management of malignant hypercalcemia. Am J Hosp Palliat Care 2011;28(7):515-7. PMID 21724679
171: Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: what do we know? J Affect Disord 2013;146(2):151-7. PMID 22985484
172: Lenherr-Taube N, Furman M, Assor E, et al. Mild idiopathic infantile hypercalcemia-part 2: a longitudinal observational study. J Clin Endocrinol Metab 2021b;106(10):2938-48. PMID 34139759
173: Lenherr-Taube N, Young EJ, Furman M, et al. Mild idiopathic infantile hypercalcemia-part 1: biochemical and genetic findings. J Clin Endocrinol Metab 2021a;106(10):2915-37. PMID 34125233
174: Letavernier E, Rodenas A, Guerrot D, Haymann JP. Williams-Beuren syndrome hypercalcemia: is TRPC3 a novel mediator in calcium homeostasis? Pediatrics 2012;129(6):e1626-30. PMID 22566418
175: Li AJ. Collip, A. M. Hanson and the isolation of the parathyroid hormone, or endocrines and enterprise. J Hist Med Allied Sci 1992;47(4):405-38. PMID 1469272
176: Li A. J.B. Collip and the development of medical research in Canada: extracts and enterprise (McGill-Queen's Associated Medical Services Studies in the History of Medicine). Montreal and Kingston, Canada: McGill-Queens University Press, 2003.
177: Li C, Zhang J, Zhu Y. Acute cardiac damage and acute kidney injury associated with hypercalcemia crisis in hyperparathyroidism: a case report. J Int Med Res 2021;49(10):3000605211050614. PMID 34686090
178: Lietman SA, Germain-Lee EL, Levine MA. Hypercalcemia in children and adolescents. Curr Opin Pediatr 2010;22(4):508-15. PMID 20601885
179: Lombardi G, Cabano R, Bollani L, Del Forno C, Stronati M. Effectiveness of pamidronate in severe neonatal hypercalcemia caused by subcutaneous fat necrosis: a case report. Eur J Pediatr 2009;168(5):625-7. PMID 18726115
180: Longcope WT. Biographical memoir of William George MacCallum: 1874-1944. Biogr Mem Nat Acad Sci 1944;23:339-64.
181: MacCallum WG, Voegtlin C. On the relation of tetany to the parathyroid glands and to calcium metabolism. J Exp Med 1909;11 (1):118-51. PMID 19867238
182: MacLeod RM. Evolutionism and Richard Owen, 1830-1868: an episode in Darwin's century. Isis 1965;56(3):259-80. PMID 5322257
183: Malihi Z, Wu Z, Stewart AW, Lawes CM, Scragg R. Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr 2016;104(4):1039-51. PMID 27604776
184: Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19(2):558-67. PMID 11208851
185: Malkin HM. History of pathology. William G. MacCallum (1874-1944). Ann Diagn Pathol 1999;3(5):328-9. PMID 10556482
186: Mandl F. Therapeutischer Versuch bein einem Falle von Ostitis fibrosa generalisata mittels exstirpation eines epithelk orperchen tumors. Zentrabl Chir 1926;5:260.
187: Manring MM, Calhoun JH. Biographical sketch: Fuller Albright, MD 1900-1969. Clin Orthop Relat Res 2011;469(8):2092-5. PMID 21384213
188: Marstrand SD, Tofteng CL, Jarløv A, Borgwardt L, Schwarz P. Concomitant familial hypocalciuric hypercalcemia and single parathyroid adenoma: a case report. J Med Case Rep 2021;15(1):471. PMID 34556169
189: Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 2000;343:1863-75. PMID 11117980
190: McDonald D, Drake MT, Crowley RK. Treatment of hypercalcaemia of malignancy in adults. Clin Med (Lond) 2023;23(5):503-7. PMID 37775175
191: McPherson ML, Prince SR, Atamer E, Maxwell DB, Ross-Clunis H, Estep H. Theophylline-induced hypercalcemia. Ann Intern Med 1986;105:52-4. PMID 3013062
192: McTaggart SJ, Craig J, MacMillan J, Burke JR. Familial occurrence of idiopathic infantile hypercalcemia. Pediatr Nephrol 1999;13(8):668-71. PMID 10502124
193: Means JH. Ward 4. Cambridge: Harvard University Press, 1958.
194: Meehan AD, Udumyan R, Kardell M, Landén M, Järhult J, Wallin G. Lithium-associated hypercalcemia: pathophysiology, prevalence, management. World J Surg 2018;42(2):415-24. PMID 29260296
195: Merlini G, Fitzpatrick L, Siris ES, et al. A human myeloma immunoglobulin binding four moles of calcium associated with asymptomatic hypercalcemia. J Clin Immunol 1984;4:185-96. PMID 6736208
196: Mesland JB, Collienne C, Laterre PF, Hantson P. Immobilization-related hypercalcemia in a COVID-19 patient with prolonged intensive care unit stay. Am J Phys Med Rehabil 2022;101(1):61-3. PMID 34657087
197: Mieher WC Jr, Thibaudeau Y, Frame B. Primary hyperparathyroidism. A diagnostic challenge. Arch Intern Med 1961;107:361-71. PMID 13770396
198: Mio K, Haruhara K, Shimizu A, et al. Hypercalcemia worsened after vitamin D supplementation in a sarcoidosis patient: A case report. Medicine (Baltimore) 2022;101(40):e30883. PMID 36221396
199: Mir SA, Masoodi SR, Wani AI, Ahmad SN, Hameed I. Calcitriol-mediated reversible hypercalcemia in a patient with primary adrenal lymphoma. Malays J Med Sci 2016;23(6):118-22. PMID 28090186
200: Monfared A, Messner A. Death following tonsillectomy in a child with Williams syndrome. Int J Pediatr Otorhinolaryngol 2006;70(6):1133-5. PMID 16406078
201: Morgan M, Nielsen S, Brixen K. Familial hypocalciuric hypercalcemia and calcium sensing receptor. Acta Clin Croat 2014;53(2):220-5. PMID 25163238
202: Motilal Nehru V, Garcia G, Ding J, Kong F, Dai Q. Humoral hypercalcemia in uterine cancers: a case report and literature review. Am J Case Rep 2017;18:22-5. PMID 28057913
203: Motlaghzadeh Y, Bilezikian JP, Sellmeyer DE. Rare causes of hypercalcemia: 2021 update. J Clin Endocrinol Metab 2021;106(11):3113-28.** PMID 34240162
204: Motoyama K, Inaba M, Emoto M, Morii H, Nishizawa Y. Sarcoidosis initially manifesting as symptomatic hypercalcemia with the absence of organic involvement. Intern Med 2002;41(6):449-52. PMID 12135177
205: Muls E, Bouillon R, Boelaert J, et al. Etiology of hypercalcemia in a patient with Addison's disease. Calcif Tissue Int 1982;39:523-6. PMID 6819071
206: Mundy GR, Guise TA. Hypercalcemia of malignancy. Am J Med 1997;103:134-44. PMID 9274897
207: Muppidi V, Meegada SR, Rehman A. Secondary hyperparathyroidism. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023. PMID 32491754
208: Murphy ML, Mattingly MJ, Meisner CT. Severe hypercalcemia in a postpartum patient. J Emerg Med 2016;51(4):e93-5. PMID 27460661
209: Nakajima K, Tamai M, Okaniwa S, et al. Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature. Endocr J 2013a;60(5):557-62. PMID 23303131
210: Nakajima N, Ueda M, Nagayama H, Yamazaki M, Katayama Y. Posterior reversible encephalopathy syndrome due to hypercalcemia associated with parathyroid hormone-related peptide: a case report and review of the literature. Intern Med 2013b;52(21):2465-8. PMID 24190154
211: Noble RL. Memories of James Bertram Collip. Can Med Assoc J 1965;93(26):1356-64. PMID 5321114
212: Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993;95(3):297-304. PMID 8368227
213: Obi Y, Mehrotra R, Rivara MB, et al. Hidden hypercalcemia and mortality risk in incident hemodialysis patients. J Clin Endocrinol Metab 2016;101(6):2440-9. PMID 27045726
214: Ohya Y, Osaki M, Sakai S, et al. A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic. BMC Neurol 2018;18(1):62. PMID 29734949
215: Otero J, Lenihan DJ. The “normothermic” Osborn wave induced by severe hypercalcemia. Texas Heart Inst J 2000;27(3):316-7. PMID 11093425
216: Otsuki K, Izuhara M, Miura S, et al. Psychosis in a primary hyperparathyroidism patient with mild hypercalcemia: A case report. Medicine (Baltimore) 2021;100(12):e25248. PMID 33761720
217: Owen R. On the anatomy of the Indian rhinoceros (Rh. unicornis). Trans Zool Soc Lond 1852;4:31-58.
218: Parks KA, Parks CG, Onwuameze OE, Shrestha S. Psychiatric complications of primary hyperparathyroidism and mild hypercalcemia. Am J Psychiatry 2017;174(7):620-22. PMID 28669204
219: Parson W. Reminiscences of Fuller Albright, 1900-1969: Gifted clinical endocrinologist of unmatched imaginative creativity. Perspec Biol Med 1995;38:459-66.
220: Patten BM, Bilezikian JP, Mallette LE, Prince AP, Engel WK, Aurbach GD. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med 1974;80:182-93. PMID 4811792
221: Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;(3):CD003474. PMID 16034900
222: Pérez-Barrios C, Hernández-Álvarez E, Blanco-Navarro I, Pérez-Sacristán B, Granado-Lorencio F. Prevalence of hypercalcemia related to hypervitaminosis D in clinical practice. Clin Nutr 2016;35(6):1354-8. PMID 26995293
223: Pérez Jurado LA, Li X, Francke U. The human calcitonin receptor gene (CALCR) at 7q21.3 is outside the deletion associated with the Williams syndrome. Cytogenet Cell Genet 1995;70(3-4):246-9. PMID 7789182
224: Pilz S, Theiler-Schwetz V, Pludowski P, et al. Hypercalcemia in pregnancy due to CYP24A1 mutations: case report and review of the literature. Nutrients 2022;14(12):2518. PMID 35745247
225: Rabinowicz S, Somech R, Yeshayahu Y. Foscarnet-related hypercalcemia during CMV treatment in an infant with SCID: a case report and review of literature. J Pediatr Hematol Oncol 2017;39(3):e173-5. PMID 27820135
226: Regal B. Richard Owen and the sea-serpent. Endeavour 2012;36(2):65-8. PMID 22305471
227: Romasovs A, Jaunozola L, Berga-Švītiņa E, Daneberga Z, Miklaševičs E, Pīrāgs V. Hypercalcemia and CYP24A1 gene mutation diagnosed in the 2nd trimester of a twin pregnancy: a case report. Am J Case Rep 2021;22:e931116. PMID 34662328
228: Rösche J, Sieveking C, Kampf C, Benecke R. Creutzfeldt-Jakob-like syndrome due to hypercalcemic encephalopathy. Clin EEG Neurosci 2015;46(4):327-30. PMID 24973231
229: Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol 2012;7(10):1722-9. PMID 22879438
230: Russo AF, Chamany K, Klemish SW, Hall TM, Murray JC. Characterization of the calcitonin/CGRP gene in Williams syndrome. Am J Med Genet 1991;39(1):28-33. PMID 1867260
231: Sadiq NM, Naganathan S, Badireddy M. Hypercalcemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023. PMID 28613465
232: Safi KH, Filbrun AG, Nasr SZ. Hypervitaminosis A causing hypercalcemia in cystic fibrosis. Case report and focused review. Ann Am Thorac Soc 2014;11(8):1244-7. PMID 25188737
233: Sakallioglu O, Hacihamdioglu B, Balamtekin N, Kalman S, Gok F. Idiopathic infantile hypercalcemia and renal involvement. Int Urol Nephrol 2008;40(2):535-7. PMID 17978858
234: Sandstrom IV. On a new gland in man and several mammals – glandulae parathyroideae. Upsala Läkareförenings Förhandlingar 1880;15:441-71.
235: Sandstrom IV Seipel CM. On a new gland in man and several mammals (glandulæ parathyroideæ). In: Charlotte H. Peters, J.F. Fulton, editors. Carl M. Seipel, translator. With biographical notes by Professor J. August Hammar. Baltimore: Johns Hopkins Press; 1938.
236: Saponaro F. Rare causes of hypercalcemia. Endocrinol Metab Clin North Am 2021;50(4):769-79.** PMID 34774247
237: Schlingmann KP. Vitamin D-dependent hypercalcemia. Endocrinol Metab Clin North Am 2021;50(4):729-42.** PMID 34774244
238: Schlingmann KP, Kaufmann M, Weber S, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011;365(5):410-21. PMID 21675912
239: Segre GV, Potts JT Jr. Differential diagnosis of hypercalcemia. In: DeGroot LJ, editor. Endocrinology. 3rd ed. Philadelphia: Saunders, 1995:1075-93.
240: Seisa MO, Nayfeh T, Hasan B, et al. A systematic review supporting the endocrine society clinical practice guideline on the treatment of hypercalcemia of malignancy in adults. J Clin Endocrinol Metab 2023;108(3):585-91. PMID 36545700
241: Shah R, Licata A, Oyesiku NM, Ioachimescu AG. Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature. Pituitary 2012;15 Suppl 1:S17-22. PMID 21188640
242: Shah RH, Martinez D. Pancreatic neuroendocrine tumor associated with humoral hypercalcemia of malignancy and carcinoid tumor: a case report and review of the literature. Pancreas 2013;42(3):549-51. PMID 23211368
243: Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 2010;362(19):1825-7. PMID 20335574
244: Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med 2000;6:442-7. PMID 10958237
245: Shinall MC Jr, Dahir KM, Broome JT. Differentiating familial hypocalciuric hypercalcemia from primary hyperparathyroidism. Endocr Pract 2013;19(4):697-702. PMID 23425644
246: Shrayyef MZ, DePapp Z, Cave WT, Wittlin SD. Hypercalcemia in two patients with sarcoidosis and Mycobacterium avium intracellulare not mediated by elevated vitamin D metabolites. Am J Med Sci 2011;342(4):336-40. PMID 21760475
247: Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab 2024;38(1):101247. PMID 30477754
248: Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int Suppl 2005;(95):S8-12. PMID 15882315
249: Silverman R, Yalow RS. Heterogeneity of parathyroid hormone. Clinical and physiologic implications. J Clin Invest 1973;52(8):1958-71. PMID 4719672
250: Simonsen JK, Rejnmark L. Endocrine disorders with parathyroid hormone-independent hypercalcemia. Endocrinol Metab Clin North Am 2021;50(4):711-20.** PMID 34774242
251: Skalova S, Cerna L, Bayer M, Kutilek S, Konrad M, Schlingmann KP. Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia. Iran J Kidney Dis 2013;7(2):160-4. PMID 23485543
252: St Goar WT. Gastrointestinal symptoms as a clue to the diagnosis of primary hyperparathyroidism: a review of 45 cases. Ann Intern Med 1957;46(1):102-18. PMID 13395220
253: Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005;352(4):373-9. PMID 15673803
254: Stewart AF, Adler M, Byers CM, Segre GR, Broadus AE. Calcium homeostasis in immobilization. N Engl J Med 1982;306:1136-40. PMID 6280047
255: Stewart AF, Hoecker J, Segre GV, Mallette LE, Amatruda T, Vignery A. Hypercalcemia in pheochromocytoma. Ann Intern Med 1985;102:776-9. PMID 3994189
256: Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med 2000;342:177-85. PMID 10639544
257: Stubbs AJ, Resnick MI. Fuller Albright (1900-1969). Invest Urol 1978;15(4):352. PMID 342447
258: Sumida A, Iizuka K, Kato T, et al. A case of familial hypocalciuric hypercalcemia type 1 due to CASR p.Pro55Leu mutation. BMC Endocr Disord 2022;22(1):164. PMID 35733207
259: Tang AR, Hinz LE, Khan A, Kline GA. Phosphate matters when investigating hypercalcemia: a mutation in SLC34A3 causing HHRH. Endocrinol Diabetes Metab Case Rep 2019;2019(1):1-6. PMID 31352694
260: Tebben PJ, Singh RJ, Kumar R. Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment. Endocr Rev 2016;37(5):521-47. PMID 27588937
261: Tonner DR, Schlechte JA. Neurologic complications of thyroid and parathyroid disease. In: Biller J, editor. The medical clinics of North America. Philadelphia: WB Saunders Company, 1993;77(1):251-63.
262: Tonon CR, Silva TAAL, Pereira FWL, et al. A review of current clinical concepts in the pathophysiology, etiology, diagnosis, and management of hypercalcemia. Med Sci Monit 2022;28:e935821. PMID 35217631
263: Tray KA, Laut J, Saidi A. Idiopathic infantile hypercalcemia, presenting in adulthood--no longer idiopathic nor infantile: two case reports and review. Conn Med 2015;79(10):593-7. PMID 26731879
264: Turken SA, Cafferty M, Silverberg SJ, et al. Neuromuscular involvement in mild asymptomatic primary hyperparathyroidism. Am J Med 1989;87:553-7. PMID 2816971
265: Utiger RD. Treatment of primary hyperparathyroidism. N Engl J Med 1999;341:1301-2. PMID 10528042
266: Valentic JD, Elias AN, Weinstein GD. Hypercalcemia associated with oral isotretinoin in the treatment of severe acne. JAMA 1983;250:1899-903. PMID 6225882
267: Varghese J, Rich T, Jimenez C. Benign familial hypocalciuric hypercalcemia. Endocr Pract 2011;17 Suppl 1:13-7. PMID 21478088
268: Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J 1999;75(887):554-6. PMID 10616693
269: Vestergaard P, Thomsen Sv. Medical treatment of primary, secondary, and tertiary hyperparathyroidism. Curr Drug Saf 2011;6(2):108-13. PMID 21524244
270: Walker MD, Shane E. Hypercalcemia: a review. JAMA 2022;328(16):1624-36.** PMID 36282253
271: Warwick OH. James Bertram Collip--1892-1965. Can Med Assoc J 1965;93:425-426. PMID 14339310
272: Wilkerson JA. Idiopathic infantile hypercalcemia, with subcutaneous fat necrosis. Am J Clin Pathol 1964;41:390-401. PMID 14159215
273: Yalow RS. Clinical significance of the heterogeneity of parathyroid hormone. Contrib Nephrol 1980;20:15-20. PMID 6995011
274: Yalow RS, Berson SA. Purification of 131-I parathyroid hormone with microfine granules of precipitated silica. Nature 1966;212(5060):357-8. PMID 4291147
275: Yasuda T, Sunami S, Ogura N, Nishioka T, Nakajima H. Infantile hypercalcemia with subcutaneous fat necrosis. Report of a case with studies on the pathogenesis of hypercalcemia. Acta Paediatr Scand 1986;75(6):1042-5. PMID 3564966
276: Younes NA, Shafagoj Y, Khatib F, Ababneh M. Laboratory screening for hyperparathyroidism. Clin Chim Acta 2005;353(1-2):1-12. PMID 15698586
277: Zajadacz B, Juszkiewicz A. Nephrocalcinosis in a 2-month-old girl suffering from a mild variant of idiopathic infantile hypercalcemia. Wiad Lek 2004;57(11-12):710-2. PMID 15865256
278: Zaman M, Raveendran L, Senay A, Sayles H, Acharya R, Dhir M. Long-term recurrence rates after surgery in primary hyperparathyroidism. J Clin Endocrinol Metab 2023;108(11):3022-30. PMID 37279502
279: Zech LA Jr, Hoeg JM. Correlating corneal arcus with atherosclerosis in familial hypercholesterolemia. Lipids Health Dis 2008;7:7. PMID 18331643
280: Zhao L, Huang L, Zhang X. Systemic lupus erythematosus-related hypercalcemia with ectopic calcinosis. Rheumatol Int 2016;36(7):1023-6. PMID 27136920
281: Zheng Z, Wu Y, Wu H, J, et al. Clinical heterogeneity and therapeutic options for idiopathic infantile hypercalcemia caused by CYP24A1 pathogenic variant. J Pediatr Endocrinol Metab 2023;36(11):999-1011. PMID 37768904
282: Zhou K, Assalita S, Williams SE. Confusion and hypercalcemia in an 80-year-old man. Cleve Clin J Med 2017;84(4):281-86. PMID 28388389
283: Zifman E, Mouler M, Eliakim A, Nemet D, Pomeranz A. Subcutaneous fat necrosis and hypercalcemia following therapeutic hypothermia--a patient report and review of the literature. J Pediatr Endocrinol Metab 2010;23(11):1185-8. PMID 21284334
284: Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcemia of malignancy. Drug Saf 1999;21:389-406. PMID 10554053

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Douglas J Lanska MD MS MSPH

Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile

Former Authors

Andrew F Stewart MD
Jeffrey L Fraser MD
Joshua M Gordon MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: heredity may be a factor

autosomal dominant
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Disorders of calcium metabolism: E83.5
ICD-11: Hypercalcaemia: 5B91.0
OMIM: Hypercalcemia, familial benign: #145980, %145981

Hypercalcemia, infantile (Williams syndrome, or Williams–Beuren syndrome): #194050

Hypercalcemia, Idiopathic infantile: #143880

Hypercalciuric hypercalcemia, benign familial: Type I: #145980

Hypercalciuric hypercalcemia, benign familial: Type II: #145981

Hypercalciuric hypercalcemia, benign familial: Type III: # 600740

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Hypercalcemia

Associated Disorders

Acute and chronic renal failure
Endocrine disorders
Familial hypocalciuric hypercalcemia
Granulomatous disorders
Infantile hypercalcemia (Williams syndrome)
- Malignancy
- Milk-alkali syndrome
- Primary hyperparathyroidism

Differential Diagnosis

primary hyperparathyroidism
malignancy
endocrine disorders
hyperthyroidism
granulomatous disorders
- sarcoidosis
- acute and chronic renal failure
- immobilization
- tumor- or treatment-related symptoms
- metabolic encephalopathy
- hyponatremia
- encephalopathy
- generalized weakness
- posterior reversible leukoencephalopathy syndrome
- hypermagnesemia
- tumor lysis syndrome
- idiopathic infantile hypercalcemia
- benign familial hypercalciuric hypercalcemia (types I-III)
- Williams syndrome (or Williams–Beuren syndrome)
- iatrogenic hypervitaminosis D
- neonatal hyperparathyroidism
- Jansen metaphyseal dysplasia
- subcutaneous fat necrosis

Also Relevant

Catatonia
Chemotherapy: Neurologic complications
Hypoparathyroidism
Leukemia: neurologic complications
Metabolic encephalopathy and metabolic coma
- Myopathies associated with parathyroid disorders
- Neuropathies associated with monoclonal gammopathies
- Nutrition and the brain
- Thyrotoxicosis

Clinical Categories

General Neurology

Patient Handouts

Williams syndrome

Web References

Clinical Trials

NIH: Hypercalcemia

	• The methods for prevention of hypercalcemia depend on the underlying disorder.
	• Only some causes of hypercalcemia are preventable (eg, vitamin D and A intoxication).
	• Intravenous bisphosphonates are effective in reducing the incidence of hypercalcemia in patients with breast cancer and known skeletal metastases.

Hypercalcemia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Table 1. Lab Studies in Primary, Secondary, and Tertiary Hyperparathyroidism

Management

Treatments with restricted indications

Special circumstances

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Brain death/death by neurologic criteria

Hepatic encephalopathy

Bowel dysfunction in neurologic disorders

Coma due to primary brainstem and diencephalic lesions

Transient visual loss

Neuroimaging in acute stroke

Sports activities: neurologic complications

Neurotechnology: brain-computer and brain-machine interfaces

This is an article preview.
Start a Free Account
to access the full version.